INVACARE (IVCRQ) 10-Q 8 Aug 22 2022 Q2 Quarterly report Financial data

DEI Document

DEI Document - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-15103
Entity Registrant Name	INVACARE CORPORATION
Entity Incorporation, State or Country Code	OH
Entity Tax Identification Number	95-2680965
Entity Address, Address Line One	One Invacare Way,
Entity Address, City or Town	Elyria,
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44035
City Area Code	440
Local Phone Number	329-6000
Title of 12(b) Security	Common Shares, without par value
Trading Symbol	IVC
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0000742112
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Shares [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		38,310,514
Class B Common Shares [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		3,667

Condensed Consolidated Statemen

Condensed Consolidated Statement of Comprehensive Income (Loss) - USD ($) shares in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net Sales		$ 189,017,000	$ 225,864,000	$ 390,005,000	$ 422,066,000
Cost of products sold		141,035,000	165,046,000	294,294,000	306,610,000
Gross Profit		47,982,000	60,818,000	95,711,000	115,456,000
Selling, general and administrative expenses		58,623,000	63,765,000	119,187,000	122,586,000
Charges related to restructuring activities		4,153,000	547,000	7,943,000	2,099,000
Operating Loss		(14,794,000)	(3,494,000)	(31,419,000)	(9,229,000)
Loss on debt extinguishment including debt finance charges and fees		0	0	0	709,000
Interest expense		6,230,000	6,084,000	12,482,000	11,815,000
Interest Income, Other		1,000	0	1,000	1,000
Loss Before Income Taxes		(21,023,000)	(9,578,000)	(43,900,000)	(21,752,000)
Income tax provision		920,000	1,120,000	2,240,000	2,990,000
Net Loss		$ (21,943,000)	$ (10,698,000)	$ (46,140,000)	$ (24,742,000)
Dividends Declared per Common Share		$ 0	$ 0	$ 0	$ 0
Net Loss per Share—Basic
Net Loss per Share—Basic		$ (0.62)	$ (0.31)	$ (1.31)	$ (0.71)
Weighted Average Shares Outstanding—Basic		35,634	34,969	35,340	34,732
Loss per Share—Assuming Dilution
Loss per Share—Assuming Dilution	[1]	$ (0.62)	$ (0.31)	$ (1.31)	$ (0.71)
Weighted Average Shares Outstanding—Assuming Dilution		35,995	35,620	35,714	35,450
Other comprehensive income (loss):
Foreign currency translation adjustments		$ (26,545,000)	$ 7,038,000	$ (32,887,000)	$ 12,715,000
Defined Benefit Plans:
Amortization of prior service costs and unrecognized losses		4,339,000	(744,000)	4,563,000	(395,000)
Deferred tax adjustment resulting from defined benefit plan activity		(38,000)	(5,000)	(85,000)	(63,000)
Valuation reserve associated with defined benefit plan activity		38,000	5,000	85,000	63,000
Current period gain (loss) on cash flow hedges		812,000	101,000	1,692,000	(774,000)
Deferred tax benefit (provision) related to gain on cash flow hedges		(184,000)	14,000	(240,000)	97,000
Other Comprehensive Income (Loss)		(21,578,000)	6,409,000	(26,872,000)	11,643,000
Comprehensive Loss		$ (43,521,000)	$ (4,289,000)	$ (73,012,000)	$ (13,099,000)
Net Sales, as a Percent of Net Sales		100%	100%	100%	100%
Cost of Products Sold, as a Percent of Net Sales		74.60%	73.10%	75.50%	72.60%
Gross Profit, as a Percent of Net Sales		25.40%	26.90%	24.50%	27.40%
Selling, general and administrative expenses, as a Percent of Net Sales		31%	28.20%	30.60%	29%
Charges related to restructuring activities, as a Percent of Net Sales		2.20%	0.20%	2%	0.50%
Operating Gain (Loss), as a Percent of Net Sales		(7.80%)	(1.50%)	(8.10%)	(2.20%)
Interest expense, as a Percent of Net Sales		3.30%	2.70%	3.20%	2.80%
Gain (loss) Before Income Taxes, as a Percent of Net Sales		(11.10%)	(4.20%)	(11.30%)	(5.20%)
Income Tax Provision, as a Percent of Net Sales		0.50%	0.50%	0.60%	0.70%
Net Gain (Loss), as a percent of Net Sales		(11.60%)	(4.70%)	(11.80%)	(5.90%)
Net loss (gain) on debt extinguishment, as a Percent of Net Sales [Line Items]					0.20%
[1]Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 43,909	$ 83,745
Trade receivables, net	90,949	117,115
Installment receivables, net	284	218
Inventories, net	138,806	144,274
Other current assets	43,097	40,036
Total Current Assets	317,045	385,388
Other Assets	6,671	5,362
Intangibles, net	26,079	26,356
Property and Equipment, net	55,884	60,921
Finance Lease, Right-of-Use Asset	59,513	63,029
Operating Lease, Right-of-Use Asset	10,679	12,600
Goodwill	336,750	355,875
Total Assets	812,621	909,531
Current Liabilities
Accounts payable	111,562	130,036
Accrued expenses	105,151	102,971
Current taxes payable	2,102	3,914
Current portion of long-term debt	2,161	3,107
Current portion of finance lease obligations	3,085	3,009
Current portion of operating lease obligations	3,551	4,217
Total Current Liabilities	227,612	247,254
Long-Term Debt	311,489	305,022
Finance Lease Long-Term Obligations	60,710	63,736
Operating Leases Long-Term Obligations	7,057	8,234
Other Long-Term Obligations	58,149	66,796
Shareholders’ Equity
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	278,788	276,665
Retained earnings (accumulated deficit)	(23,495)	22,645
Accumulated other comprehensive income (loss)	(9,884)	16,988
Treasury Shares (4,535 and 4,397 shares at June 30, 2022 and December 31, 2021, respectively)	(107,939)	(107,788)
Total Shareholders’ Equity	147,604	218,489
Total Liabilities and Shareholders’ Equity	812,621	909,531
Common Shares [Member]
Shareholders’ Equity
Common Shares	10,132	9,977
Class B Common Shares [Member]
Shareholders’ Equity
Common Shares	$ 2	$ 2

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - shares shares in Thousands	Jun. 30, 2022	Dec. 31, 2021
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	4,535	4,397
Common Shares [Member]
Common Stock, Shares Authorized	150,000	150,000
Common Stock, Shares, Issued	40,147	39,416
Class B Common Shares [Member]
Common Stock, Shares Authorized	12,000	12,000
Common Stock, Shares, Issued	4	4

Condensed Consolidated Statem_2

Condensed Consolidated Statement Of Cash Flows $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Purchases of capped calls	$ 0	$ (18,787)
Convertible Debt Discount Amortization and Accretion	1,828	1,747
Cash and cash equivalents		78,252
Effect of exchange rate changes on cash	(2,348)	1,488
Operating Activities
Net loss	(46,140)	(24,742)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	7,848	8,264
Amortization of operating lease right of use assets	2,572	3,201
Provision for losses on trade and installment receivables	318	335
Provision for deferred income taxes	98	460
Provision for other deferred liabilities	(589)	(65)
Provision for equity compensation	2,278	5,810
Gain on disposals of property and equipment	(38)	(175)
Loss on debt extinguishment including debt finance charges and fees	0	709
Amortization of debt fees	1,230	1,035
Changes in operating assets and liabilities:
Trade receivables	22,503	(10,388)
Installment sales contracts, net	210	289
Inventories, net	512	(27,082)
Other current assets	(3,013)	5,770
Accounts payable	(14,929)	22,872
Accrued expenses	931	(24,406)
Other long-term liabilities	(2,561)	316
Net Cash Provided by (Used in) Operating Activities	(26,942)	(36,050)
Investing Activities
Purchases of property and equipment	(2,764)	(9,047)
Proceeds from sale of property and equipment	5	23
Change in other long-term assets	(32)	(69)
Other	(4)	0
Net Cash Used by Investing Activities	(2,787)	(9,093)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	9,292	147,539
Repurchases of convertible debt, payments on revolving lines of credit and finance leases	(15,633)	(105,216)
Payment of financing costs	(1,267)	(5,175)
Purchases of capped calls	0	(18,787)
Purchases of treasury shares	(151)	(1,752)
Net Cash Used by Financing Activities	(7,759)	16,609
Effect of exchange rate changes on cash	(2,348)	1,488
Cash, Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(39,836)	(27,046)
Cash and cash equivalents at beginning of year	$ 83,745	105,298
Cash and cash equivalents at end of period		$ 78,252

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Shareholders' Equity Statement - USD ($)	Total	Common Stock [Member]	Common Stock [Member] Class B Common Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]
Total Shareholders’ Equity at Dec. 31, 2020	$ 333,846,000	$ 9,816,000	$ 2,000	$ 326,088,000	$ 58,538,000	$ 45,436,000	$ (106,034,000)
Purchases of capped calls	(18,787,000)
Total Shareholders’ Equity at Mar. 31, 2021	282,701,000	9,917,000	2,000	273,982,000	54,164,000	50,670,000	(106,034,000)
Total Shareholders’ Equity at Dec. 31, 2020	333,846,000	9,816,000	2,000	326,088,000	58,538,000	45,436,000	(106,034,000)
Allocated Share-based Compensation Expense	1,381,000	52,000		1,997,000			(668,000)
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	2,677,000	109,000		3,652,000			(1,084,000)
Net Loss	(24,742,000)				(24,742,000)
Foreign currency translation adjustments	12,715,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	12,715,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	(677,000)					(677,000)
Amortization of prior service costs and unrecognized losses	(395,000)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax	(395,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(13,099,000)
Adoption of ASU 2020-06	(25,128,000)			(34,798,000)	9,670,000
Purchases of capped calls	(18,787,000)			(18,787,000)
Total Shareholders’ Equity at Jun. 30, 2021	280,890,000	9,977,000	2,000	278,152,000	43,466,000	57,079,000	(107,786,000)
Total Shareholders’ Equity at Mar. 31, 2021	282,701,000	9,917,000	2,000	273,982,000	54,164,000	50,670,000	(106,034,000)
Allocated Share-based Compensation Expense	713,000	52,000		1,329,000			(668,000)
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	1,765,000	8,000		2,841,000			(1,084,000)
Net Loss	(10,698,000)				(10,698,000)
Foreign currency translation adjustments	7,038,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	7,038,000
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	115,000					115,000
Amortization of prior service costs and unrecognized losses	(744,000)
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax	(744,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(4,289,000)
Total Shareholders’ Equity at Jun. 30, 2021	280,890,000	9,977,000	2,000	278,152,000	43,466,000	57,079,000	(107,786,000)
Total Shareholders’ Equity at Dec. 31, 2021	218,489,000	9,977,000	2,000	276,665,000	22,645,000	16,988,000	(107,788,000)
Allocated Share-based Compensation Expense	(319,000)	0		(319,000)			0
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	2,446,000	155,000		2,442,000			(151,000)
Net Loss	(46,140,000)				(46,140,000)
Foreign currency translation adjustments	(32,887,000)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(32,887,000)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	1,452,000					1,452,000
Amortization of prior service costs and unrecognized losses	4,563,000
Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax	4,563,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(73,012,000)
Purchases of capped calls	0
Total Shareholders’ Equity at Jun. 30, 2022	147,604,000	10,132,000	2,000	278,788,000	(23,495,000)	(9,884,000)	(107,939,000)
Total Shareholders’ Equity at Mar. 31, 2022	189,308,000	9,977,000	2,000	276,975,000	(1,552,000)	11,694,000	(107,788,000)
Allocated Share-based Compensation Expense	26,000	0		26,000			0
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	1,791,000	155,000		1,787,000			(151,000)
Net Loss	(21,943,000)				(21,943,000)
Foreign currency translation adjustments	(26,545,000)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(26,545,000)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	628,000					628,000
Amortization of prior service costs and unrecognized losses	4,339,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(43,521,000)
Total Shareholders’ Equity at Jun. 30, 2022	$ 147,604,000	$ 10,132,000	$ 2,000	$ 278,788,000	$ (23,495,000)	$ (9,884,000)	$ (107,939,000)

Accounting Policies

Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Accounting Policies	Accounting Policies Principles of Consolidation: The condensed consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of June 30, 2022 and the results of its operations and changes in its cash flow for the six months ended June 30, 2022 and 2021, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a May 31 quarter end to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year. Use of Estimates: The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. Recent Accounting Pronouncements (Already Adopted): In March 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting," which is intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates if certain criteria are met. The guidance may be adopted in any period prior to the guidance expiration on December 31, 2022.

Receivables

Receivables	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Receivables	Receivables Receivables consist of the following (in thousands): June 30, 2022 December 31, 2021 Accounts receivable, gross $ 113,612 $ 142,806 Customer rebate reserve (10,696) (12,267) Cash discount reserves (7,746) (9,179) Allowance for doubtful accounts (3,261) (3,642) Other, principally returns and allowances reserves (960) (603) Accounts receivable, net $ 90,949 $ 117,115 Reserves for customer rebates and cash discounts are recorded as a reduction in revenue and netted against gross accounts receivable. Customer rebates in excess of a given customer's accounts receivable balance are classified in Accrued Expenses. Customer rebates and cash discounts are estimated based on the most likely amount principle as well as historical experience and anticipated performance. In addition, customers have the right to return product within the company’s normal terms policy, and as such, the company estimates the expected returns based on an analysis of historical experience and adjusts revenue accordingly. During the third quarter of 2021, the company entered into an agreement with a bank to sell certain trade receivables with governmental entity customers in the Nordic region without recourse. Under ASC 860, the sale of the receivables qualify as a true sale and not a secured borrowing. No gain or loss was recorded on the sale of the receivables. Bank charges, which are recorded as interest expense attributable to the program, were immaterial for the six months ended June 30, 2022. Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all the company’s receivables are due from health care, medical equipment providers and long-term care facilities predominantly located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, are ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The company's approach is to separate its receivables into good-standing and collection receivables. Good-standing receivables are assigned to risk pools of high, medium and low. The risk pools are driven by the specifics associated with the geography of origination. Expected loss percentages are calculated and assigned to each risk pool, driven primarily by historical experience. The historical loss percentages are calculated for each risk pool and then judgmentally revised to consider current risk factors as well as consideration of the impact of forecasted events, as applicable. The expected loss percentages are then applied to receivables balances each period to determine the allowance for doubtful accounts. In North America, excluding Canada, good-standing receivables are assigned to the low risk pool and assigned an expected loss percentage of 1.0% as these receivables are deemed to share the same risk profile and collections efforts are the same. Installment receivables in North America are characterized as collection receivables and thus reserves are based on specific analysis of each customer. In Canada, good-standing receivables are deemed low risk and assigned a loss percentage of 0.1%. In Europe, expected losses are determined by each location in each region. Most locations have a majority of their receivables assigned to the low risk pool, which has an average expected loss percentage of 0.3%. About half of the locations have a portion of their receivables assigned as medium risk with an average expected loss percentage of 0.9%. Only a few locations have any receivables characterized as high risk and the average credit loss percentage for those locations is 3.4%. Collection risk is generally low as payment terms in certain key markets, such as Germany, are immediate and in many locations the ultimate customer is the government. In the Asia Pacific region, receivables are characterized as low risk, which have an average expected loss percentage of 1.0%. Historical losses are low in this region where the use of credit insurance is often customary. The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): Six Ended Balance as of beginning of period $ 3,642 Current period provision 318 Recoveries (direct write-offs), net (699) Balance as of end of period $ 3,261 The company did not make any material changes to the assignment of receivables to the different risk pools or to the expected loss reserves in the quarter. The company is monitoring the impacts of the COVID-19 pandemic and the possibility for an impact on collections, but to date this has not materially impacted 2022. For collections receivables, the estimated allowance for uncollectible amounts is based primarily on management’s evaluation of the financial condition of each customer. In addition, as a result of the company's financing arrangement with DLL, a third-party financing company which the company has worked with since 2000, management monitors the collection status of these contracts in accordance with the company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishes reserves for specific customers as needed. The company writes off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. Refer to Concentration of Credit Risk in the notes to the condensed consolidated financial statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the condensed consolidated balance sheets. The company has recorded a contingent liability in the amount of $302,000 related to the contingent aspect of the company's guarantee associated with its arrangement with DLL. The contingent liability is recorded applying the same expected loss model used for the trade and installment receivables recorded on the company's books. Specifically, historical loss history is used to determine the expected loss percentage, which is then adjusted judgmentally to consider other factors, as needed. The company’s U.S. customers electing to finance their purchases can do so using DLL. Repurchased DLL receivables recorded on the books of the company represent a single portfolio segment of receivables to the independent provider channel and long-term care customers. The portfolio segment of these receivables are distinguished by geography and credit quality. These receivables were repurchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by three payments. The estimated allowance for uncollectible amounts and evaluation for both classes of installment receivables is based on the company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed. The company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the company’s ability to enforce judgments, liens, etc. For purposes of granting or extending credit, the company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for most customers desiring credit greater than $250,000, which generally includes a detailed review of the customer’s financial statements as well as consideration of other factors such as exposure to changing reimbursement laws. Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the company goes through a legal process for pursuing collection of outstanding amounts, the length of which typically approximates eighteen months. Any write-offs are made after the legal process has been completed. Installment receivables consist of the following (in thousands): June 30, 2022 December 31, 2021 Current Long-Term Total Current Long-Term Total Installment receivables $ 284 $ 393 $ 677 $ 218 $ 734 $ 952 Allowance for doubtful accounts — — — — — — Installment receivables, net $ 284 $ 393 $ 677 $ 218 $ 734 $ 952 No Installment receivables were purchased from DLL during the six months ended June 30, 2022. No sales of installment receivables were made by the company during the quarter. The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): Six Months Ended June 30, 2022 Year Ended December 31, 2021 Balance as of beginning of period $ — $ 487 Current period provision (benefit) — (75) Direct write-offs charged against the allowance — (412) Balance as of end of period $ — $ — Installment receivables by class as of June 30, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-Impaired installment receivables with no related allowance recorded 677 677 — — Total Non-Impaired installment receivables with no related allowance recorded 677 677 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 677 $ 677 $ — $ — Installment receivables by class as of December 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 952 952 — — Total Non-impaired installment receivables with no related allowance recorded 952 952 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 952 $ 952 $ — $ — The aging of the company’s installment receivables was as follows (in thousands): June 30, 2022 December 31, 2021 Total Asia Pacific Total Asia Pacific Current $ 655 $ 655 $ 952 $ 952 0-30 days past due 22 22 — — 31-60 days past due — — — — 61-90 days past due — — — — 90+ days past due — — — — $ 677 $ 677 $ 952 $ 952

Inventories

Inventories	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories, Net Inventories consist of the following (in thousands): June 30, 2022 December 31, 2021 Raw materials $ 65,053 $ 69,371 Finished goods 62,481 62,124 Work in process 11,272 12,779 Inventories, net $ 138,806 $ 144,274

Other Current Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets Other current assets consist of the following (in thousands): June 30, 2022 December 31, 2021 Tax receivables principally value added taxes $ 26,894 $ 21,943 Prepaid insurance 1,436 4,462 Prepaid inventory and freight 2,138 2,394 Recoverable income taxes 2,205 2,301 Derivatives (foreign currency forward exchange contracts) 2,058 386 Receivable due from information technology provider 898 612 Service contracts 980 304 Deferred financing fees 404 379 Prepaid and other current assets 6,084 7,255 Other Current Assets $ 43,097 $ 40,036

Other Long-Term Assets

Other Long-Term Assets	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Long-Term Assets	Other Long-Term Assets Other long-term assets consist of the following (in thousands): June 30, 2022 December 31, 2021 Cash surrender value of life insurance policies $ 2,528 $ 2,481 Deferred financing fees 2,052 409 Deferred income taxes 1,535 1,540 Installment receivables 393 734 Investments 85 86 Other 78 112 Other Long-Term Assets $ 6,671 $ 5,362

Property And Equipment

Property And Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property And Equipment	Property and Equipment Property and equipment consist of the following (in thousands): June 30, 2022 December 31, 2021 Machinery and equipment $ 272,818 $ 278,347 Capitalized software 30,921 30,448 Land, buildings and improvements 25,873 27,299 Furniture and fixtures 8,191 8,943 Leasehold improvements 4,861 6,782 Property and Equipment, gross 342,664 351,819 Accumulated depreciation (286,780) (290,898) Property and Equipment, net $ 55,884 $ 60,921 Machinery and equipment includes demonstration units placed in provider locations which are depreciated to their estimated recoverable values over their estimated useful lives. In the fourth quarter of 2019, the company initiated the first stage of an Enterprise Resource Planning ("ERP") software implementation. Related to the ERP project, the company capitalized certain costs in accordance with ASC 350 as shown in capitalized software above. The net book value of capitalized software was $27,680,000 and $28,715,000 at June 30, 2022 and December 31, 2021, respectively. Depreciation expense related to capitalized software started in 2021 and was $833,000 and $1,510,000 for the three and six months ended June 30, 2022, respectively, compared to $413,000 and $665,000 for the three and six months ended June 30, 2021, respectively. Unpaid purchases of property and equipment at June 30, 2022 and December 31, 2021 were $0 and $1,090,000, respectively and are excluded from purchases of property and equipment on the condensed consolidated statements of cash flows for the periods ending and are included in subsequent periods when paid.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The change in goodwill from December 31, 2021 to June 30, 2022 was due to foreign currency translation. In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill is tested annually for impairment or whenever events or changes in circumstances indicate the carrying value of a reporting unit could be above its fair value. A reporting unit is defined as an operating segment or one level below. The company has determined that its reporting units are North America, Europe and Asia Pacific. Refer to Goodwill in the company's Annual Report on Form 10-K for the period ending December 31, 2021 for further disclosure regarding the company's impairment analysis review methodology.

Intangibles

Intangibles	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangibles	Intangibles The company's intangibles consist of the following (in thousands): June 30, 2022 December 31, 2021 Historical Accumulated Historical Accumulated Customer lists $ 50,078 $ 50,078 $ 52,447 $ 52,447 Trademarks 22,961 — 24,137 — Developed technology 7,342 6,952 7,652 7,149 Patents 5,522 5,522 5,543 5,543 License agreements 4,019 1,300 2,905 1,196 Other 1,149 1,140 1,147 1,140 Intangibles $ 91,071 $ 64,992 $ 93,831 $ 67,475 All of the company’s intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for trademarks shown above, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2021 to June 30, 2022 were primarily the result of foreign currency translation on historical cost and accumulated amortization as well as new license agreements. The company evaluates the carrying value of definite-lived assets annually in the fourth quarter and whenever events or circumstances indicate possible impairment. Definite-lived assets are determined to be impaired if the future undiscounted cash flows expected to be generated by the asset are less than the carrying value. Actual impairment amounts for definite-lived assets are then calculated using a discounted cash flow calculation. Any impairment for indefinite-lived intangible assets is calculated as the difference between the future discounted cash flows expected to be generated by the asset less than the carrying value for the asset. Amortization expense related to intangible assets was $207,000 in the first six months of 2022 and is expected to be $604,000 in 2022, $619,000 in 2023, $473,000 in 2024, $439,000 in 2025, $437,000 in 2026 and $311,000 in 2027. Amortized intangible assets are being amortized on a straight-line basis over remaining lives of 3 to 8 years with a weighted average remaining life of approximately 6.0 years.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consist of accruals for the following (in thousands): June 30, 2022 December 31, 2021 Taxes other than income taxes, primarily value added taxes $ 28,628 $ 23,217 Salaries and wages 20,350 24,012 Warranty 9,511 11,198 Professional 9,475 8,697 Freight 6,830 5,460 Derivative liabilities (foreign currency forward exchange contracts) 5,000 1,938 IT service contracts 4,021 4,013 Interest 3,264 3,297 Severance 2,744 400 Product liability, current portion 2,496 2,362 Deferred revenue 2,404 4,156 Rebates 1,062 6,569 Insurance 622 625 Supplemental executive retirement program liability 391 391 Rent 59 196 Other items, principally trade accruals 8,294 6,440 Accrued Expenses $ 105,151 $ 102,971 Generally, the company's products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sales to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. In addition, the company has sold extended warranties that, while immaterial, require the company to defer the revenue associated with those warranties until earned. The company has established procedures to appropriately defer such revenue. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product field action and recalls, which could require additional warranty reserve provision. Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold. Rebates are netted against gross accounts receivables. If rebates are in excess of such receivables, they are then classified as accrued expenses. The reduction in accrued rebates from December 31, 2021 to June 30, 2022 primarily relates to payments principally made in the first quarter each year, earned from the previous year. The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): Balance as of January 1, 2022 $ 11,198 Warranties provided during the period 1,498 Settlements made during the period (3,293) Changes in liability for pre-existing warranties during the period, including expirations 108 Balance as of June 30, 2022 $ 9,511

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt Disclosure	Long-Term Debt Debt consists of the following (in thousands): June 30, 2022 December 31, 2021 Convertible senior notes at 4.50%, due in June 2022 — 2,642 Convertible senior notes Series I at 5.00%, due in November 2024 72,274 72,140 Convertible senior notes Series II at 5.00%, due November 2024 80,248 78,251 Convertible senior notes at 4.25%, due in March 2026 119,745 119,036 Other obligations 41,383 36,060 313,650 308,129 Less current maturities of long-term debt (2,161) (3,107) Long-Term Debt $ 311,489 $ 305,022 On September 30, 2015, the company entered into an Amended and Restated Revolving Credit and Security Agreement, which was subsequently amended and then amended and restated on July 26, 2022 (the “Prior Credit Agreement”) which was to mature on January 16, 2024. The Prior Credit Agreement was entered into by and among the company, certain of the company’s direct and indirect U.S. and Canadian subsidiaries and certain of the company’s European subsidiaries, certain other of the company’s direct and indirect U.S., Canadian and European subsidiaries, and PNC Bank, National Association (“PNC”), JPMorgan Chase Bank, N.A., J.P. Morgan Europe Limited, KeyBank National Association, and Citizens Bank, National Association. PNC is the administrative agent (the “Prior Credit Agreement Administrative Agent”) and J.P. Morgan Europe Limited is the European agent (the “European Agent”) under the Prior Credit Agreement. In connection with entering into the company's Prior Credit Agreement, the company incurred fees which were capitalized and are being amortized as interest expense. As of June 30, 2022, debt fees yet to be amortized totaled $625,000. The company had outstanding letters of credit of $3,392,000 and $3,450,000 as of June 30, 2022 and December 31, 2021, respectively. Outstanding letters of credit and other reserves impacting borrowing capacity were $4,015,000 and $2,585,000 as of June 30, 2022 and December 31, 2021, respectively. The company had outstanding borrowings of $25,950,000 under its North America Credit Facility as of June 30, 2022. The company had outstanding borrowings of $8,803,000 (€8,200,000) under its French Credit Facility and $4,412,000 (£3,500,000) under its UK Credit Facility as of June 30, 2022, together referred to as the European Credit Facility. The company had outstanding borrowings of $22,150,000 under its North America Credit Facility as of December 31, 2021. The company had outstanding borrowings of $7,366,000 (€6,500,000) under its French Credit Facility and $5,986,000 (£4,500,000) under its UK Credit Facility as of December 31, 2021, together referred to as the European Credit Facility. The weighted average interest rate on all borrowings, excluding finance leases, was 4.5% for the six months ended June 30, 2022 and 4.5% for the year ended December 31, 2021. North America Borrowers Credit Facility For the company's North America Borrowers, the Prior Credit Agreement provided for an asset-based-lending senior secured revolving credit facility which is secured by substantially all the company’s U.S. and Canadian assets, other than real estate. The Prior Credit Agreement provided the company and the other Borrowers with a credit facility in an aggregate principal amount of $60,000,000, subject to availability based on a borrowing base formula, under a senior secured revolving credit, letter of credit and swing line loan facility (the “North America Credit Facility”). Up to $20,000,000 of the North America Credit Facility was available for issuance of letters of credit. The aggregate principal amount of the North America Credit Facility could have been increased by up to $25,000,000 to the extent requested by the company and agreed to by any lender or new financial institution approved by the Prior Credit Agreement Administrative Agent. The aggregate borrowing availability under the North America Credit Facility was determined based on a borrowing base formula. The aggregate usage under the North America Credit Facility could not exceed an amount equal to the sum of (a) 85% of eligible U.S. accounts receivable plus (b) the lesser of (i) 70% of eligible U.S. inventory and eligible foreign in-transit inventory and (ii) 85% of the net orderly liquidation value of eligible U.S. inventory and eligible foreign in-transit inventory (not to exceed $4,000,000), plus (c) the lesser of (i) 80% of the net orderly liquidation value of U.S. eligible machinery and equipment and (ii) $0 as of June 30, 2022 (subject to reduction as provided in the Prior Credit Agreement), plus (d) 85% of eligible Canadian accounts receivable, plus (e) the lesser of (i) 70% of eligible Canadian inventory and (ii) 85% of the net orderly liquidation value of eligible Canadian inventory, less (f) swing loans outstanding under the North America Credit Facility, less (g) letters of credit issued and undrawn under the North America Credit Facility, less (h) a $3,000,000 minimum availability reserve, less (i) other reserves required by the Prior Credit Agreement Administrative Agent, and in each case subject to the definitions and limitations in the Prior Credit Agreement. As of June 30, 2022, the company was in compliance with all covenant requirements. As of June 30, 2022, the company had gross borrowing base of $41,324,000 and net borrowing availability of $26,809,000 under the North America Credit Facility under the Prior Credit Agreement, considering the minimum availability reserve, then-outstanding letters of credit, other reserves and the $7,500,000 dominion trigger amount described below. Interest will accrue on outstanding indebtedness under the Prior Credit Agreement at the SOFR rate, plus a margin ranging from 2.25% to 2.75%, or at the alternate base rate, plus a margin ranging from 1.25% to 1.75%, as selected by the company. Borrowings under the North America Credit Facility are subject to commitment fees of 0.25% or 0.375% per year, depending on utilization. The Prior Credit Agreement contained customary representations, warranties and covenants. Exceptions to the operating covenants in the Prior Credit Agreement provide the company with flexibility to, among other things, enter into or undertake certain sale and leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Prior Credit Agreement, as amended. The Prior Credit Agreement also contained a covenant requiring the company to maintain minimum availability under the North America Credit Facility of not less than (i) 12.5% of the maximum amount that may be drawn under the North America Credit Facility for five (5) consecutive business days, or (ii) 11.25% of the maximum amount that may be drawn under the North America Credit Facility on any business day. The company also is subject to dominion triggers under the North America Credit Facility requiring the company to maintain borrowing capacity of not less than $7,500,000 on any business day or any five consecutive days in order to avoid triggering full control by an agent for the lenders of the company's cash receipts for application to the company’s obligations under the agreement. The Prior Credit Agreement contained customary default provisions, with certain grace periods and exceptions, which provide for events of default that include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption of any material manufacturing facilities for more than 10 consecutive days. The proceeds of the North America Credit Facility were used to finance the working capital and other business needs of the company. There was $25,950,000 of outstanding borrowings under the North America Credit Facility on June 30, 2022. European Credit Facility The Prior Credit Agreement also provided for a revolving credit, letter of credit and swing line loan facility which gives the company and the European Borrowers the ability to borrow up to an aggregate principal amount of $30,000,000, with a $5,000,000 sublimit for letters of credit and a $2,000,000 sublimit for swing line loans (the “European Credit Facility”). Up to $15,000,000 of the European Credit Facility was available to each of Invacare Limited (the “UK Borrower”) and Invacare Poirier SAS (the “French Borrower” and, together with the UK Borrower, the “European Borrowers”). The aggregate borrowing availability for each European Borrower under the European Credit Facility is determined based on a borrowing base formula. The aggregate borrowings of each of the European Borrowers under the European Credit Facility may not exceed an amount equal to (a) 85% of the European Borrower’s eligible accounts receivable, less (b) the European Borrower’s borrowings and swing line loans outstanding under the European Credit Facility, less (c) the European Borrower’s letters of credit issued and undrawn under the European Credit Facility, less (d) a $3,000,000 minimum availability reserve, less (e) other reserves required by the European Agent, and in each case subject to the definitions and limitations in the Prior Credit Agreement. As of June 30, 2022, the gross borrowing base to the European Borrowers under the European Credit Facility was $19,955,000 and the net borrowing availability was $13,205,000, considering the $3,000,000 minimum availability reserve and a $3,750,000 dominion trigger amount described below. Borrowing availability is based on a prior month base in USD. Actual borrowings in GBP and EUR fluctuate in USD between date of borrowing and when translated for consolidated reporting. The aggregate principal amount of the European Credit Facility could have been increased by up to $10,000,000 to the extent requested by the company and agreed to by any lender or Lenders that wished to increase their lending participation or, if not agreed to by any lender, a new financial institution that agreed to join the European Credit Facility and that was approved by the Prior Credit Agreement Administrative Agent and the European Agent. Interest was accrued on outstanding indebtedness under the European Credit Facility at the SOFR rate, plus a margin ranging from 2.50% to 3.00%, or for swing line loans, at the overnight SOFR rate, plus a margin ranging from 2.50% to 3.00%, as selected by the company. The margin was adjusted quarterly based on utilization. Borrowings under the European Credit Facility were subject to commitment fees of 0.25% or 0.375% per year, depending on utilization. The European Credit Facility was secured by substantially all the personal property assets of the UK Borrower and its in-country subsidiaries, and all the receivables of the French Borrower and its in-country subsidiaries. The UK and French facilities (which comprised the European Credit Facility) were cross collateralized, and the US personal property assets previously pledged under the North America Credit Facility also served as collateral for the European Credit Facility. The European Credit Facility was subject to customary representations, warranties and covenants generally consistent with those applicable to the North America Credit Facility. Exceptions to the operating covenants in the Prior Credit Agreement provided the company with flexibility to, among other things, enter into or undertake certain sale/leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Prior Credit Agreement. The Prior Credit Agreement also contained a covenant requiring the European Borrowers to maintain undrawn availability under the European Credit Facility of not less than (i) 12.5% of the maximum amount that may be drawn under the European Credit Facility for five (5) consecutive business days, or (ii) 11.25% of the maximum amount that may be drawn under the European Credit Facility on any business day. The European Borrowers also were subject to cash dominion triggers under the European Credit Facility requiring the European Borrower to maintain borrowing capacity of not less than $3,750,000 on any business day or $3,750,000 for five consecutive business days in order to avoid triggering full control by an agent for the lenders of the European Borrower’s cash receipts for application to its obligations under the European Credit Facility. The European Credit Facility was subject to customary default provisions, with certain grace periods and exceptions, consistent with those applicable to the North America Credit Facility, which provide that events of default include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, cross-default, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption in the operations of any material manufacturing facility for more than 10 consecutive days. The proceeds of the European Credit Facility were used to finance the working capital and other business needs of the company. As of June 30, 2022, the company had borrowings of $8,803,000 (€8,200,000) under its French Credit Facility and $4,412,000 (£3,500,000) under its UK Credit Facility as of June 30, 2022, together referred to as the European Credit Facility. The company had outstanding borrowings of $7,366,000 (€6,500,000) under its French Credit Facility and $5,986,000 (£4,500,000) under its UK Credit Facility as of December 31, 2021. The company was in compliance with the Prior Credit Agreement covenants at June 30, 2022. In January 2021, the Prior Credit Agreement was amended to provide for, among other things, the addition of the company's Netherlands subsidiary as a guarantor under the European Credit Facility, amendments to the restrictive covenants in the Prior Credit Agreement to (1) increase the maximum amount of permitted miscellaneous indebtedness to $30,000,000 from $10,000,000 and (2) permit up to $9,000,000 of financing based on certain European public and government receivables, and terms that, upon the occurrence of certain events related to a transition from the use of LIBOR, permit the agent for the lenders to amend the Prior Credit Agreement to replace the LIBOR rate and/or the Euro rate with a benchmark replacement rate. In March 2021, the Prior Credit Agreement was further amended to permit the issuance of the 2026 Notes and the capped call transactions entered into by the company in connection with the issuance of the 2026 Notes, as further discussed in the sections below. On December 29, 2021, the Prior Credit Agreement was further amended with the primary provisions to replace the references to the LIBOR rate or Euro rate to a term secured overnight finance rate ("SOFR"). On July 26, 2022, the Prior Credit Agreement was amended and restated. Refer to the July 2022 Financings section at the end of this footnote. Convertible senior notes due 2022 In the second quarter of 2017, the company issued $120,000,000 aggregate principal amount of 4.50% Convertible Senior Notes due 2022 (the “2022 Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2022 Notes bear interest at a rate of 4.50% per year payable semi-annually in arrears on June 1 and December 1 of each year, beginning December 1, 2017. Prior to December 1, 2021, the 2022 Notes were convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Prior to May 16, 2019, the 2022 Notes were convertible, subject to certain conditions, into cash only. On May 16, 2019, the company obtained shareholder approval under applicable New York Stock Exchange rules such that conversion of the 2022 Notes may be settled in cash, the company’s Common Shares or a combination of cash and the company’s Common Shares, at the company’s election. Exchange transactions were completed in the second quarter of 2020 and the repurchase of debt was completed in the first quarter of 2021, as further discussed below. The 2022 Notes matured on June 1, 2022. At maturity, $2,650,000 principal amount of the 2022 Notes were outstanding, which the company repaid in cash. Holders of the 2022 Notes could convert their 2022 Notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2021 only under the following circumstances: (1) during any fiscal quarter commencing after September 30, 2017 (and only during such fiscal quarter), if the last reported sale price of the company’s Common Shares for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter was greater than or equal to 130% of the applicable conversion price for the 2022 Notes on each applicable trading day; (2) during the five Holders of the 2022 Notes had the right to require the company to repurchase all or some of their 2022 Notes at 100% of their principal, plus any accrued and unpaid interest, upon the occurrence of certain fundamental changes. The initial conversion rate is 61.6095 Common Shares per $1,000 principal amount of 2022 Notes (equivalent to an initial conversion price of approximately $16.23 per common share). Until the company received shareholder approval on May 16, 2019 authorizing it to elect to settle future conversions of the 2022 Notes in common shares, the company separately accounted for the conversion features as a derivative. The derivative was capitalized on the balance sheet as a long-term liability with adjustment to reflect fair value each quarter until the change to the conversion features as a result of the shareholder approval received on May 16, 2019 resulted in the termination of the derivative. The fair value of the convertible debt conversion liability at issuance was $28,859,000. The company recognized a loss of $6,193,000 in 2019 related to the convertible debt conversion liability. In connection with the offering of the 2022 Notes, the company entered into privately negotiated convertible note hedge transactions with one financial institution (the “option counterparty”). These transactions cover, subject to customary anti-dilution adjustments, the number of the company’s Common Shares that will initially underlie the 2022 Notes and are expected generally to reduce the potential equity dilution, and/or offset any cash payments in excess of the principal amount due, as the case may be, upon conversion of the 2022 Notes. The company evaluated the note hedges under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the note hedges should be accounted for as derivatives. These derivatives were capitalized on the balance sheet as long-term assets and were adjusted to reflect fair value each quarter. The fair value of the convertible note hedge assets at issuance was $24,780,000. The company entered into separate, privately negotiated warrant transactions with the option counterparty at a higher strike price relating to the same number of the company’s Common Shares, subject to customary anti-dilution adjustments, pursuant to which the company sold warrants to the option counterparties. The warrants could have a dilutive effect on the company’s outstanding Common Shares and the company’s earnings per share to the extent that the price of the company’s Common Shares exceeds the strike price of those warrants. The initial strike price of the warrants is $21.4375 per share and is subject to certain adjustments under the terms of the warrant transactions. The company evaluated the warrants under the applicable accounting literature, including Derivatives and Hedging , ASC 815, and determined that the warrants meet the definition of a derivative, are indexed to the company's own shares and should be classified in shareholders' equity. The amount paid for the warrants and capitalized in shareholders' equity was $14,100,000. All note hedge options relating to the 2022 Notes expired on June 1, 2022. Warrants relating to the 2022 Notes outstanding on June 30, 2022 were 7,393,141. If exercised, one common share is issued upon exercise of each warrant, but may be adjusted under certain circumstances if the relevant share price exceeds the warrant strike price for the relevant measurement period at the time of exercise. Common Shares are reserved for issuance upon exercise of the remaining warrants relating to the 2022 Notes at two Common Shares per warrant. The warrants will begin to expire on September 1, 2022 and then partially expire on each trading day over the 220 trading day period following September 1, 2022. The net proceeds from the offering of the 2022 Notes were approximately $115,289,000, after deducting fees and offering expenses of $4,711,000, which were paid in 2017. These debt issuance costs were capitalized and were amortized as interest expense through June 2022. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. A portion of the net proceeds from the offering were used to pay the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds to the company from the warrant transactions), which net cost was $10,680,000. During the second quarter of 2020, the company entered into separate, privately negotiated agreements with certain holders of the company's previously outstanding convertible notes due 2021 (the "2021 Notes") and certain holders of its 2022 Notes to exchange $35,375,000 in aggregate principal amount of 2021 Notes and $38,500,000 in aggregate principal amount of 2022 Notes, for aggregate consideration of $73,875,000 in aggregate principal amount of new Series II 2024 Notes and $5,593,000 in cash. During the first quarter of 2021, the company repurchased $78,850,000 in principal amount of 2022 Notes, resulting in a loss on debt extinguishment of $709,000. The liability components of the 2022 Notes consist of the following (in thousands): June 30, 2022 December 31, 2021 Principal amount of liability component $ — $ 2,650 Debt fees — (8) Net carrying amount of liability component $ — $ 2,642 The effective interest rate on the liability component was 10.9% upon original issuance including consideration of the discount. Total interest expense subsequent to adoption of ASU 2020-06 includes coupon interest and amortization of debt fees. Interest expense of $20,000 and $50,000 was accrued for the three and six months ended June 30, 2022 compared to $30,000 and $799,000 for the three and six months ended June 30, 2021, based on the stated coupon rate of 4.5%. The effective interest rate of the 2022 Notes as of June 30, 2022 was 5.4%. The 2022 Notes were not convertible as of June 30, 2022, nor was the applicable conversion threshold met. Convertible senior notes Series I due 2024 During the fourth quarter of 2019, the company entered into separate privately negotiated agreements with certain holders of its 2021 Notes to exchange $72,909,000 in aggregate principal amount of 2021 Notes for aggregate consideration of $72,909,000 in aggregate principal amount of new 5.00% Convertible Senior Exchange Notes due 2024 (the “Series I 2024 Notes”) of the company and $6,928,000 in cash. The notes bear interest at a rate of 5.00% per year payable semi-annually in arrears on May 15 and November 15 of each year, beginning May 15, 2020. The notes will mature on November 15, 2024, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to May 15, 2024, the Series I 2024 Notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The Series I 2024 Notes may be settled in cash, the company’s Common Shares or a combination of cash and the company’s Common Shares, at the company’s election. Prior to the maturity of the Series I 2024 Notes, the company may, at its election, redeem for cash all or part of the Series I 2024 Notes if the last reported sale price of the company’s Common Shares equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the company provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Series I 2024 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date (subject to certain limited exceptions). No sinking fund is provided for the Series I 2024 Notes, which means the company is not required to redeem or retire the Series I 2024 Notes periodically. Holders of the Series I 2024 Notes may convert their Series I 2024 Notes at their option at any time prior to the close of business on the business day immediately preceding May 15, 2024 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the company’s Common Shares for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Series I 2024 Notes on each applicable trading day; (2) during the five A loss of $5,885,000 was recorded a part of the exchange transaction, which included the write-off of fees related to the portion of the 2021 Notes exchanged. Debt issuance costs of $1,394,000 were capitalized and are being amortized as interest expense through November 15, 2024. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The liability components of the Series I 2024 Notes consist of the following (in thousands): June 30, 2022 December 31, 2021 Principal amount of liability component $ 72,909 $ 72,909 Debt fees (635) (769) Net carrying amount of liability component $ 72,274 $ 72,140 The effective interest rate on the liability component was 8.8% upon original issuance including consideration of the discount. Total interest expense subsequent to adoption of ASU 2020-06 includes coupon interest and amortization of debt fees. Interest expense of $912,000 and $1,823,000 was accrued for the three and six months ended June 30, 2022 compared to $911,000 and $1,822,000 for the three and six months ended June 30, 2021 based on the stated coupon rate of 5.0%. The effective interest rate of the Series I 2024 Notes as of June 30, 2022 was 5.4%. The Series I 2024 Notes were not convertible as of June 30, 2022 nor was the applicable conversion threshold met. Convertible senior notes Series II due 2024 During the second quarter of 2020, the company entered into separate, privately negotiated agreements with certain holders of its 2021 Notes and certain holders of its 2022 Notes to exchange $35,375,000 in aggregate principal amount of 2021 Notes and $38,500,000 in aggregate principal amount of 2022 Notes, for aggregate consideration of $73,875,000 in aggregate principal amount of new 5.00% Series II Convertible Senior Exchange Notes due 2024 (the “Series II 2024 Notes”) of the company and $5,593,000 in cash. The Series II 2024 Notes bear interest at a rate of 5.00% per year, payable semi-annually in arrears on May 15 and November 15 of each year, beginning November 15, 2020. The Series II 2024 Notes will mature on November 15, 2024, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to May 15, 2024, the Series II 2024 Notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The Series II 2024 Notes may be settled in cash, the company’s Common Shares or a combination of cash and the company’s Common Shares, at the company’s election. Prior to the maturity of the Series II 2024 Notes, the company may, at its election, redeem for cash all or part of the Series II 2024 Notes, if the last reported sale price of the company’s Common Shares equals or exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the company provides notice of redemption. The redemption price will be equal to 100% of the accreted principal amount of the Series II 2024 Notes to be redeemed, plus any accrued and unpaid interest, if any, on the original principal amount of the New Notes redeemed to, but excluding, the redemption date (subject to certain limited exceptions). No sinking fund is provided for the Series II 2024 Notes, which means the company is not required to redeem or retire the Series II 2024 Notes periodically. Holders of the Series II 2024 Notes may convert their Series II 2024 Notes at their option at any time prior to the close of business on the business day immediately preceding May 15, 2024 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending June 30, 2020 (and only during such calendar quarter), if the last reported sale price of the company’s Common Shares for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 130% of the conversion price for the Series II 2024 Notes on each applicable trading day; (2) during the five The principal amount of the Series II 2024 Notes also will accrete at a rate of approximately 4.7% per year commencing June 4, 2020, compounding on a semi-annual basis. The accreted portion of the principal is payable in cash upon maturity but does not bear interest and is not convertible into the company’s Common Shares. The total amount accreted as of June 30, 2022 was $7,175,000, of which $917,000 and $1,828,000 was for the three and six months ended June 30, 2022, respectively, compared to $877,000 and $1,747,000 for the three and six months ended June 30, 2021, respectively. Remaining accretion until maturity (at current principal) was $9,447,000 at June 30, 2022. A loss of $6,599,000 was recorded a part of the exchange transaction, which included the write-off of fees related to portions of the 2021 Notes and 2022 Notes exchanged. Debt issuance costs of $1,505,000 were capitalized and are being amortized as interest expense through November 2024. Debt issuance costs are presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The liability components of the Series II 2024 Notes consist of the following (in thousands): June 30, 2022 December 31, 2021 Principal amount of liability component - including accretion $ 81,051 $ 79,222 Debt fees (803) (971) Net carrying amount of liability component $ 80,248 $ 78,251 The effective interest rate on the liability component was 9.0% upon original issuance including consideration of the discount. Total interest expense subsequent to adoption of ASU 2020-06 includes coupon interest, accretion and amortization of debt fees. Interest expense for accretion of $917,000 and $1,828,000 was recognized for the three and six months ended June 30, 2022 compared to $877,000 and $1,747,000 for the three and six months ended June 30, 2021. Interest expense of $924,000 and $1,847,000 were recognized for the three and six months ended June 30, 2022 compared to $924,000 and $1,847,000 for the three and six months ended June 30, 2021, based on the stated coupon rate of 5.0%. The effective interest rate of the Series II 2024 Notes as of June 30, 2022 including cou

Other Long-Term Obligations

Other Long-Term Obligations	6 Months Ended
	Jun. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Long-Term Obligations	Other Long-Term Obligations Other long-term obligations consist of the following (in thousands): June 30, 2022 December 31, 2021 Deferred income taxes $ 20,961 $ 21,664 Product liability 11,644 11,342 Deferred compensation 5,384 6,174 Deferred gain on sale leaseback 5,005 5,174 Supplemental executive retirement plan liability 4,833 5,106 Death benefit obligation plan 3,654 4,568 Pension 3,109 7,814 Uncertain tax obligation including interest 3,093 3,171 Other 466 1,783 Other Long-Term Obligations $ 58,149 $ 66,796 On April 23, 2015, the company entered into a real estate sale leaseback transaction which resulted in the company recording an initial deferred gain of $7,414,000, the majority of which is included in Other Long-Term Obligations and will be recognized over the 20-year life of the leases. The gains realized were $82,000 and $163,000 for the three and six months ended June 30, 2022 respectively, compared to $79,000 and $157,000 for the three and six months ended June 30, 2021 respectively.

Leases and Commitments (Notes)

Leases and Commitments (Notes)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lessee, Finance Leases	Leases and Commitments The company reviews new contracts to determine if the contracts include a lease. To the extent a lease agreement includes an extension option that is reasonably certain to be exercised, the company has recognized those amounts as part of the right-of-use assets and lease liabilities. The company combines lease and certain non-lease components, such as common area maintenance, in the calculation of the lease assets and related liabilities. As most lease agreements do not provide an implicit rate, the company uses an incremental borrowing rate (IBR) based on information available at commencement date in determining the present value of lease payments and to help classify the lease as operating or financing. The company calculates its IBR based on the secured rates of the company's recent debt issuances, the credit rating of the company, changes in currencies, lease repayment timing as well as other publicly available data. The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses associated with operating the facilities and equipment. As of June 30, 2022, the company is committed under non-cancelable leases, which have initial or remaining terms in excess of one year and expire on various dates through 2040. On April 23, 2015, the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000, which were used to reduce debt under the U.S. and Canadian Credit Facility . The initial total annual rent for the properties was $2,275,000 and can increase annually over the 20-year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four finance leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties were required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the condensed consolidated balance sheets. Lease expenses for the three and six months ended June 30, 2022 and June 30, 2021, respectively, were as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Operating leases $ 1,420 $ 1,819 $ 3,030 $ 3,781 Variable and short-term leases 631 1,010 1,345 2,061 Total operating leases $ 2,051 $ 2,829 $ 4,375 $ 5,842 Finance lease interest cost $ 1,079 $ 1,163 $ 2,162 $ 2,341 Finance lease depreciation 1,063 1,266 2,155 2,542 Total finance leases $ 2,142 $ 2,429 $ 4,317 $ 4,883 Future minimum operating and finance lease commitments, as of June 30, 2022, are as follows (in thousands): Finance Operating Leases 2022 $ 3,416 $ 2,325 2023 6,772 2,990 2024 6,716 2,254 2025 6,620 1,798 2026 6,508 1,104 Thereafter 68,436 1,634 Total future minimum lease payments 98,468 12,105 Amounts representing interest (34,673) (1,497) Present value of minimum lease payments 63,795 10,608 Less: current maturities of lease obligations (3,085) (3,551) Long-term lease obligations $ 60,710 $ 7,057 Supplemental cash flow amounts for the three and six months ended June 30, 2022 and June 30, 2021 were as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, Cash Activity: Cash paid in measurement of amounts for lease liabilities 2022 2021 2022 2021 Operating leases $ 2,060 $ 2,897 $ 4,299 $ 5,917 Finance leases 1,839 2,102 3,668 4,211 Total $ 3,899 $ 4,999 $ 7,967 $ 10,128 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations 2022 2021 2022 2021 Operating leases $ 449 $ 590 $ 1,165 $ 4,429 Finance leases 740 181 915 6,156 Total $ 1,189 $ 771 $ 2,080 $ 10,585 Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of June 30, 2022 and December 31, 2021, respectively: June 30, 2022 December 31, 2021 Weighted-average remaining lease term - finance leases 15.2 years 15.8 years Weighted-average remaining lease term - operating leases 4.9 years 5.0 years Weighted-average discount rate - finance leases 6.42% 6.43% Weighted-average discount rate - operating leases 7.08% 7.10%
Lessee, Operating Leases	Leases and Commitments The company reviews new contracts to determine if the contracts include a lease. To the extent a lease agreement includes an extension option that is reasonably certain to be exercised, the company has recognized those amounts as part of the right-of-use assets and lease liabilities. The company combines lease and certain non-lease components, such as common area maintenance, in the calculation of the lease assets and related liabilities. As most lease agreements do not provide an implicit rate, the company uses an incremental borrowing rate (IBR) based on information available at commencement date in determining the present value of lease payments and to help classify the lease as operating or financing. The company calculates its IBR based on the secured rates of the company's recent debt issuances, the credit rating of the company, changes in currencies, lease repayment timing as well as other publicly available data. The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses associated with operating the facilities and equipment. As of June 30, 2022, the company is committed under non-cancelable leases, which have initial or remaining terms in excess of one year and expire on various dates through 2040. On April 23, 2015, the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000, which were used to reduce debt under the U.S. and Canadian Credit Facility . The initial total annual rent for the properties was $2,275,000 and can increase annually over the 20-year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four finance leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties were required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the condensed consolidated balance sheets. Lease expenses for the three and six months ended June 30, 2022 and June 30, 2021, respectively, were as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Operating leases $ 1,420 $ 1,819 $ 3,030 $ 3,781 Variable and short-term leases 631 1,010 1,345 2,061 Total operating leases $ 2,051 $ 2,829 $ 4,375 $ 5,842 Finance lease interest cost $ 1,079 $ 1,163 $ 2,162 $ 2,341 Finance lease depreciation 1,063 1,266 2,155 2,542 Total finance leases $ 2,142 $ 2,429 $ 4,317 $ 4,883 Future minimum operating and finance lease commitments, as of June 30, 2022, are as follows (in thousands): Finance Operating Leases 2022 $ 3,416 $ 2,325 2023 6,772 2,990 2024 6,716 2,254 2025 6,620 1,798 2026 6,508 1,104 Thereafter 68,436 1,634 Total future minimum lease payments 98,468 12,105 Amounts representing interest (34,673) (1,497) Present value of minimum lease payments 63,795 10,608 Less: current maturities of lease obligations (3,085) (3,551) Long-term lease obligations $ 60,710 $ 7,057 Supplemental cash flow amounts for the three and six months ended June 30, 2022 and June 30, 2021 were as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, Cash Activity: Cash paid in measurement of amounts for lease liabilities 2022 2021 2022 2021 Operating leases $ 2,060 $ 2,897 $ 4,299 $ 5,917 Finance leases 1,839 2,102 3,668 4,211 Total $ 3,899 $ 4,999 $ 7,967 $ 10,128 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations 2022 2021 2022 2021 Operating leases $ 449 $ 590 $ 1,165 $ 4,429 Finance leases 740 181 915 6,156 Total $ 1,189 $ 771 $ 2,080 $ 10,585 Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of June 30, 2022 and December 31, 2021, respectively: June 30, 2022 December 31, 2021 Weighted-average remaining lease term - finance leases 15.2 years 15.8 years Weighted-average remaining lease term - operating leases 4.9 years 5.0 years Weighted-average discount rate - finance leases 6.42% 6.43% Weighted-average discount rate - operating leases 7.08% 7.10%

Revenue Revenue

Revenue Revenue	6 Months Ended
	Jun. 30, 2022
Revenue [Abstract]
Revenue Recognition, Deferred Revenue [Policy Text Block]	Revenue The company has two revenue streams: products and services. Services include repair, refurbishment, preventive maintenance and rental of products. Services for the North America segment include maintenance and repair of products. Services for the Europe segment include repair, refurbishment and preventive maintenance services. Services in All Other, are in the Asia Pacific region, and include rental and repair of products. The following tables disaggregate the company’s revenues by major source and by reportable segment for the three and six months ended June 30, 2022 and June 30, 2021 (in thousands): Three Months Ended June 30, 2022 Product Service Total Europe $ 109,479 $ 3,289 $ 112,768 North America 68,525 193 68,718 All Other 6,305 1,226 7,531 Total $ 184,309 $ 4,708 $ 189,017 % Split 98% 2% 100% Six Months Ended June 30, 2022 Product Service Total Europe $ 224,744 $ 6,103 $ 230,847 North America 143,708 329 144,037 All Other 12,687 2,434 15,121 Total $ 381,139 $ 8,866 $ 390,005 % Split 98% 2% 100% Three Months Ended June 30, 2021 Product Service Total Europe $ 118,165 $ 3,131 $ 121,296 North America 95,985 262 96,247 All Other 7,044 1,277 8,321 Total $ 221,194 $ 4,670 $ 225,864 % Split 98% 2% 100% Six Months Ended June 30, 2021 Product Service Total Europe $ 228,009 $ 6,062 $ 234,071 North America 171,687 534 172,221 All Other 13,222 2,552 15,774 Total $ 412,918 $ 9,148 $ 422,066 % Split 98% 2% 100% The company's revenues are principally related to the sale of products, approximately 98%, with the remaining 2% related to services including repair, refurbishment, preventive maintenance and rental of products. While the company has a significant amount of contract types, the sales split by contract type is estimated as follows: general terms and conditions (30%), large national customers (23%), governments, principally pursuant to tender contracts (22%) and other customers including buying groups and independent customers (25%). All product revenues and substantially all service revenues are recognized at a point in time. The remaining service revenue, recognized over time, are reflected in the Europe segment and include multiple performance obligations. For such contracts, the company allocates revenue to each performance obligation based on its relative standalone selling price. The company generally determines the standalone selling price based on the expected cost-plus margin methodology. Revenue is recognized when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the company’s products and services. The amount of consideration received and revenue recognized by the company can vary as a result of variable consideration terms included in the contracts related to customer rebates, cash discounts and return policies. Revenue is measured as the amount of consideration probable of not having a significant reversal of cumulative revenue recognized when related uncertainties are resolved. Customer rebates and cash discounts are estimated based on the most likely amount principle and these estimates are based on historical experience and anticipated performance. In addition, customers have the right to return products within the company’s normal terms policy, and as such the company estimates the expected returns based on an analysis of historical experience. The company adjusts its estimate of revenue at the earlier of when the most likely amount of consideration it expects to receive changes or when the consideration becomes fixed. The company generally does not expect that there will be significant changes to its estimates of variable consideration (refer to “Receivables” and "Accrued

Equity Compensation

Equity Compensation	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Shareholders' Equity Transactions	Equity Compensation The company’s Common Shares have a $0.25 stated value. The Common Shares and the Class B Common Shares generally have identical rights, terms and conditions and vote together as a single class on most issues, except that the Class B Common Shares have ten votes per share and, in general, can only be transferred to family members or for estate planning purposes. Holders of Class B Common Shares are entitled to convert their shares into Common Shares at any time on a share-for-share basis. When Class B Common Shares are transferred out of a familial relationship, they automatically convert to Common Shares. As of June 30, 2022, 3,667 Class B Common Shares remained outstanding. Prior conversions of Class B Common Shares have virtually eliminated the company’s dual class voting structure. As of June 30, 2022, the holders of the Common Shares represented approximately 99.9% of the company’s total outstanding voting power. Equity Compensation Plan On May 17, 2018, the shareholders of the company approved the Invacare Corporation 2018 Equity Compensation Plan (the “2018 Plan”), which was adopted on March 27, 2018 by the company's Board of Directors (the “Board”). The company’s Board adopted the 2018 Plan in order to authorize additional Common Shares for grant as equity compensation, and to reflect changes to Section 162(m) of the Internal Revenue Code (the “Code”) resulting from the U.S. Tax Cuts and Jobs Act of 2017. Following shareholder approval of the 2018 Plan, all of the Common Shares then-remaining available for issuance under the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”) and all of the Common Shares that were forfeited or remained unpurchased or undistributed upon termination or expiration of awards under the 2013 Plan and under the Invacare Corporation 2003 Performance Plan (the “2003 Plan”), become available for issuance under the 2018 Plan. Awards granted previously under the 2013 Plan and 2003 Plan will remain in effect under their original terms. The 2018 Plan uses a fungible share-counting method, under which each Common Share underlying an award of stock options or stock appreciation rights ("SAR") will count against the number of total shares available under the 2018 Plan as one share; and each Common Share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2018 Plan as two shares. Shares underlying awards made under the 2003 Plan or 2013 Plan that are forfeited or remain unpurchased or undistributed upon termination or expiration of the awards will become available under the 2018 Plan for use in future awards. Any Common Shares that are added back to the 2018 Plan as the result of forfeiture, termination or expiration of an award granted under the 2018 Plan or the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2018 Plan or 2013 Plan, as applicable. Each Common Share that is added back to the 2018 Plan due to a forfeiture, termination or expiration of an award granted under the 2003 Plan will be added back as one Common Share. The Compensation and Management Development Committee of the Board (the “Compensation Committee”), in its discretion, may grant an award under the 2018 Plan to any director or employee of the company or an affiliate. As of June 30, 2022, 2,362,474 Common Shares were available for future issuance under the 2018 Plan in connection with the following types of awards with respect to the company's Common Shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock and performance shares. The Compensation Committee also may grant performance units that are payable in cash. The Compensation Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards. The 2018 Plan provides that shares granted come from the company's authorized but unissued Common Shares or treasury shares. In addition, the company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the company acquiring treasury shares. The amounts of equity-based compensation expense recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): For the Six Months Ended June 30, 2022 2021 Restricted stock and restricted stock units $ 2,597 $ 3,761 Performance shares and performance share units (319) 2,049 Total stock-based compensation expense $ 2,278 $ 5,810 As of June 30, 2022, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan and previous plans, which is related to non-vested awards, was as follows (in thousands): June 30, 2022 Restricted stock and restricted stock units $ 4,864 Performance shares and performance share units 1,354 Total unrecognized stock-based compensation expense $ 6,218 Total unrecognized compensation cost will be adjusted for future changes in actual and estimated forfeitures and for updated vesting assumptions for the performance share awards (refer to "Performance Shares and Performance Share Units" below). No tax benefits for stock compensation were realized during the three and six months ended June 30, 2022 and 2021, respectively, due to a valuation allowance against deferred tax assets. In accordance with ASC 718, any tax benefits resulting from tax deductions in excess of the compensation expense recognized is classified as a component of financing cash flows. Stock Options Generally, non-qualified stock option awards have a term of ten years and were granted with an exercise price per share equal to the fair market value of the company’s Common Shares on the date of grant. The following table summarizes information about stock option activity for the six months ended June 30, 2022: Weighted Average Options outstanding at January 1, 2022 750,159 $ 12.69 Expired (3,000) 17.47 Options outstanding at June 30, 2022 747,159 $ 12.67 Options exercise price range at June 30, 2022 $ 12.15 to $ 14.49 Options exercisable at June 30, 2022 747,159 Shares available for grant under the 2018 Plan at June 30, 2022* 2,362,474 ________ * Shares available for grant under the 2018 Plan as of June 30, 2022 are reduced by awards and increased by forfeitures or expirations. At June 30, 2022, an aggregate of 805,637 Common Shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer. The following table summarizes information about stock options outstanding at June 30, 2022: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Exercisable at Weighted Average $12.15 – $20.00 747,159 3.5 $ 12.67 747,159 $ 12.67 The 2018 Plan provides for a one-year minimum vesting period for stock options and, generally, options must be exercised within ten years from the date granted. No stock options were issued in 2022 or 2021. Restricted Stock and Restricted Stock Units The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): Weighted Average Fair Value Stock / Units unvested at January 1, 2022 1,160,847 $ 8.17 Granted 1,017,055 1.48 Vested (549,774) 8.43 Forfeited (131,256) 6.94 Stock / Units unvested at 1,496,872 $ 3.64 The restricted awards generally vest ratably over the three years after the award date. Unearned restricted awards compensation, determined as the market value of the shares at the date of grant, is being amortized on a straight-line basis over the vesting period as adjusted for forfeiture estimates. Performance Shares and Performance Share Units The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): Weighted Average Fair Value Shares / Units unvested at January 1, 2022 972,288 $ 7.76 Granted 460,187 1.48 Shares / Units unvested at 1,432,475 $ 5.75 During the six months ended June 30, 2022, performance shares and performance share units (for non-U.S. recipients) were granted. Performance awards have a three year performance period with payouts based on achievement of certain performance goals. The awards are classified as equity awards as they will be settled in Common Shares upon vesting. The number of shares earned will be determined at the end of the three-year performance period based on achievement of performance criteria for January 1, 2020 through December 31, 2022, January 1, 2021 through December 31, 2023 and January 1, 2022 through December 31, 2024, respectively established by the Compensation Committee at the time of grant. Recipients will be entitled to receive a number of Common Shares equal to the number of performance shares that vest based upon the levels of achievement which may range between 0% and 150% of the target number of shares with the target being 100% of the initial grant. The fair value of the performance awards is based on the stock price on the date of grant discounted for the estimated value of dividends foregone as the awards are not eligible for dividends except to the extent vested. The grant fair value is further updated each reporting period while variable accounting applies. The company assesses the probability that the performance targets will be met with expense recognized whenever it is probable that at least the minimum performance criteria will be achieved. Depending upon the company's assessment of the probability of achievement of the goals, the company may not recognize any expense associated with performance awards in a given period, may reverse prior expense recorded or record additional expense to recognize the cumulative estimated achievement level of proportionate term of the award. Performance award compensation expense is generally expected to be recognized over three years. The company continues to recognize expense (benefit) related to the awards granted in 2020, 2021 and 2022 as it is considered probable that the performance goals for those awards will be met.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) by Component	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss) by Component	Accumulated Other Comprehensive Income (Loss) by Component Changes in accumulated other comprehensive income (loss) ("OCI") (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total March 31, 2022 $ 12,193 $ 2,553 $ (3,877) $ 825 $ 11,694 OCI before reclassifications (25,540) (1,005) 4,299 1,263 (20,983) Amount reclassified from accumulated OCI — — 40 (635) (595) Net current-period OCI (25,540) (1,005) 4,339 628 (21,578) June 30, 2022 $ (13,347) $ 1,548 $ 462 $ 1,453 $ (9,884) Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988 OCI before reclassifications (32,308) (579) 4,617 2,138 (26,132) Amount reclassified from accumulated OCI — — (54) (686) (740) Net current-period OCI (32,308) (579) 4,563 1,452 (26,872) June 30, 2022 $ (13,347) $ 1,548 $ 462 $ 1,453 $ (9,884) Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total March 31, 2021 $ 53,131 $ 2,358 $ (3,325) $ (1,494) $ 50,670 OCI before reclassifications 7,250 (212) (701) (369) 5,968 Amount reclassified from accumulated OCI — — (43) 484 441 Net current-period OCI 7,250 (212) (744) 115 6,409 June 30, 2021 $ 60,381 $ 2,146 $ (4,069) $ (1,379) $ 57,079 Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2020 $ 50,329 $ (517) $ (3,674) $ (702) $ 45,436 OCI before reclassifications 10,052 2,663 (231) (1,587) 10,897 Amount reclassified from accumulated OCI — — (164) 910 746 Net current-period OCI 10,052 2,663 (395) (677) 11,643 June 30, 2021 $ 60,381 $ 2,146 $ (4,069) $ (1,379) $ 57,079 Reclassifications out of accumulated OCI were as follows (in thousands): Amount reclassified from OCI Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Defined Benefit Plans Service and interest costs $ 40 $ (43) $ (54) $ (164) Selling, general and administrative expenses Tax — — — — Income taxes Total after tax $ 40 $ (43) $ (54) $ (164) Derivatives Foreign currency forward contracts hedging sales $ (30) $ 159 $ (57) $ 181 Net sales Foreign currency forward contracts hedging purchases (703) 386 (734) 838 Cost of products sold Total loss (income) before tax (733) 545 (791) 1,019 Tax 98 (61) 105 (109) Income taxes Total after tax $ (635) $ 484 $ (686) $ 910

Charges Related To Restructurin

Charges Related To Restructuring Activities	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Charges Related To Restructuring Activities	Charges Related to Restructuring Activities The company's restructuring charges were originally necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affected the company's customers (e.g. home health care providers) and continued pricing pressures faced by the company due to the outsourcing by competitors to lower cost locations. Restructuring decisions were also the result of reduced profitability in each of the segments. Restructuring actions have continued into 2022. For the six months ended June 30, 2022, severance and other charges totaled $7,943,000 which were related to North America of $3,202,000, Europe of $4,732,000 and All Other of $9,000. Payments for the six months ended June 30, 2022 were $4,424,000 and the cash payments were funded with the company's cash on hand. The 2022 charges are expected to be paid out within 12 months. For the six months ended June 30, 2021, charges totaled $2,099,000 which were related to North America of $853,000 and Europe of $1,246,000. In North America costs were incurred related to severance. The European charges were for severance costs $862,000 and contract terminations $384,000, primarily related to the closure of a German manufacturing facility. Payments for the six months ended June 30, 2021 were $6,824,000 and the cash payments were funded with company's cash on hand. There have been no material changes in accrued balances related to the charges, either as a result of revisions to the plans or changes in estimates. In addition, the savings anticipated as a result of the company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting selling, general and administrative expenses, and to a lesser extent, costs of products sold. To date, the company's liquidity has been sufficient to absorb these charges and payments. A progression by reporting segment of the accruals recorded as a result of the restructuring for the six months ended June 30, 2022 is as follows (in thousands): Severance Other Total December 31, 2021 Balances North America $ 482 $ — $ 482 Total 482 — 482 Charges North America 1,124 538 1,662 Europe 2,119 — 2,119 All Other 9 9 Total 3,252 538 3,790 Payments North America (422) (538) (960) Europe (367) — (367) All Other (9) — (9) Total (798) (538) (1,336) March 31, 2022 Balances North America 1,184 — 1,184 Europe 1,752 — 1,752 Total $ 2,936 $ — $ 2,936 Charges North America $ 542 998 $ 1,540 Europe 1,288 1,325 2,613 Total 1,830 2,323 4,153 Payments North America (768) (442) (1,210) Europe (1,254) (624) (1,878) Total (2,022) (1,066) (3,088) June 30, 2022 Balances North America 958 556 1,514 Europe 1,786 701 2,487 Total $ 2,744 $ 1,257 $ 4,001

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The company had an effective tax rate of 4.4% and 5.1% on losses before tax for the three and six months ended June 30, 2022, respectively, compared to an expected benefit of 21.0% on the pre-tax loss for each period. The company had an effective tax rate of 11.7% and 13.7% on losses before tax for the three and six months ended June 30, 2021, respectively, compared to an expected benefit of 21.0% on the pre-tax loss for each period. The company's effective tax rate for the three and six months ended June 30, 2022 and June 30, 2021 were unfavorable as compared to the U.S. federal statutory rate, principally due to the negative impact of the company not being able to record tax benefits related to the significant losses in countries which had tax valuation allowances. The effective tax rate was increased for the three and six months ended June 30, 2022 and June 30, 2021 by certain taxes outside the United States, excluding countries with tax valuation allowances, that were at an effective rate higher than the U.S. statutory rate.

Net Earnings (Loss) Per Common

Net Earnings (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Earnings (Loss) Per Common Share	Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated. (In thousands except per share data) For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Basic Weighted average common shares outstanding 35,634 34,969 35,340 34,732 Net loss $ (21,943) $ (10,698) $ (46,140) $ (24,742) Net loss per common share $ (0.62) $ (0.31) $ (1.31) $ (0.71) Diluted Weighted average common shares outstanding 35,634 34,969 35,340 34,732 Share options and awards 361 651 374 718 Weighted average common shares assuming dilution 35,995 35,620 35,714 35,450 Net loss $ (21,943) $ (10,698) $ (46,140) $ (24,742) Net loss per common share * $ (0.62) $ (0.31) $ (1.31) $ (0.71) ________ * Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss. For the three and six months ended June 30, 2022, shares associated with equity compensation awards of 2,680,850 and 1,268,582, respectively, and for the three and six months ended June 30, 2021, shares associated with equity compensation awards of 1,058,264 and 1,056,714, respectively, were excluded from the weighted average common shares assuming dilution as incremental shares were antidilutive. At June 30, 2022, the majority of the antidilutive incremental shares were awards granted at an exercise price above $12.14, which was higher than the average fair market value price of $1.32 and $1.73 for the three and six months ended June 30, 2022. At June 30, 2021, the majority of the antidilutive incremental shares were awards granted at an exercise price above $24.45, which was higher than the average fair market value price of $8.33 and $8.81 for the three and six months ended June 30, 2021. For the three and six months ended June 30, 2022 and June 30, 2021, respectively, no shares were included in the common shares assuming dilution related to the company's issued warrants as the average market price of the company shares for these periods did not exceed the strike price of the warrants.

Concentration Of Credit Risk

Concentration Of Credit Risk	6 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Concentration Of Credit Risk	Concentration of Credit Risk The company manufactures and distributes durable medical equipment to the home health care, retail and extended care markets. The company performs credit evaluations of its customers’ financial condition. The company utilizes De Lage Landen, Inc. (“DLL”), a third-party financing company, to provide lease financing to Invacare's U.S. customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a recourse obligation of $1,019,000 at June 30, 2022 to DLL for events of default under the contracts, which total $6,613,000 at June 30, 2022. Guarantees, ASC 460, requires the company to record a guarantee liability as it relates to the limited recourse obligation. As such, the company has recorded an immaterial liability for this guarantee obligation within other long-term obligations. The company's recourse is reevaluated by DLL biannually, considers activity between the biannual dates and excludes any receivables purchased by the company from DLL. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4 . Credit losses are provided for in the financial statements. Substantially all the company’s receivables are due from health care, medical equipment providers and long-term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe or also direct from governmental entities in certain countries. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. Changes in these programs can have a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company’s customers.

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives ASC 815 requires companies to recognize all derivative instruments in the condensed consolidated balance sheets as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. Cash Flow Hedging Strategy The company uses derivative instruments in an attempt to manage its exposure to transactional foreign currency exchange risk. Foreign forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. The company recognizes its derivative instruments as assets or liabilities in the condensed consolidated balance sheets measured at fair value. All of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the condensed consolidated statements of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months. The company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the company generally limits its hedges to between 50% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, most of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $38,664,000 and $58,115,000 matured during the six months ended June 30, 2022 and June 30, 2021, respectively, compared to $27,998,000 and $31,448,000 during the three month ended June 30, 2022 and June 30, 2021, respectively. Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): June 30, 2022 December 31, 2021 Notional Unrealized Notional Unrealized USD / EUR 23,147 1,452 — — USD / CAD 11,750 (49) — — EUR / GBP 9,353 181 — — EUR / NOK 3,932 19 — — NOK / SEK 2,313 (16) — — USD / MXN 2,209 106 23 1 $ 52,704 $ 1,693 $ 23 $ 1 Derivatives Not Qualifying or Designated for Hedge Accounting Treatment The company utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the company in 2022 or 2021 related to these contracts and the associated short-term intercompany trading receivables and payables. Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2022 and 2021, respectively, and outstanding were as follows (in thousands USD): June 30, 2022 December 31, 2021 Notional Gain Notional Gain USD / AUD $ 1,299 $ 1 $ 3,792 $ (57) USD / CAD 19,084 (10) 14,556 (24) USD / EUR 80,306 (2,954) 70,454 (1,104) USD / DKK 12,352 (714) 10,850 (257) USD / GBP 3,717 (63) 4,028 32 USD / NOK 5,352 (579) 2,352 (81) USD / SEK 2,152 (196) 2,344 (131) EUR / GBP 5,928 115 — — EUR / NOK 5 — — — AUD / NZD 7,517 (36) 7,366 (17) USD / THB 4,270 (46) 4,500 86 EUR / SEK 6,797 (153) — — $ 148,779 $ (4,635) $ 120,242 $ (1,553) The fair values of the company’s derivative instruments were as follows (in thousands): June 30, 2022 December 31, 2021 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ 1,782 $ 89 $ 1 $ — Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 276 4,911 385 1,938 Total derivatives $ 2,058 $ 5,000 $ 386 $ 1,938 The fair values of the company’s foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the condensed consolidated balance sheets. The effect of derivative instruments on Accumulated Other Comprehensive Income (Loss) (OCI) and the condensed consolidated Statements of comprehensive income (loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Three months ended June 30, 2022 Foreign currency forward exchange contracts $ 1,263 $ 635 $ 115 Six months ended June 30, 2022 Foreign currency forward exchange contracts $ 2,138 $ 686 $ 115 Three months ended June 30, 2021 Foreign currency forward exchange contracts $ (369) $ (484) $ (88) Six months ended June 30, 2021 Foreign currency forward exchange contracts $ (1,587) $ (910) $ (88) Derivatives (foreign currency forward exchange contracts) not designated as hedging Amount of Gain (Loss) Three months ended June 30, 2022 Foreign currency forward exchange contracts $ (5,237) Six months ended June 30, 2022 Foreign currency forward exchange contracts $ (4,635) Three months ended June 30, 2021 Foreign currency forward exchange contracts $ 264 Six months ended June 30, 2021 Foreign currency forward exchange contracts $ (723) The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales and in cost of products sold for hedges of inventory purchases. For the three and six months ended June 30, 2022, net sales were increased by $30,000 and $57,000, while cost of products sold was decreased by $703,000 and $734,000 for net pre-tax realized gains of $733,000 and $791,000, respectively. For the three and six months ended June 30, 2021, net sales were decreased by $159,000 and $181,000 while cost of products sold was increased by $386,000 and $838,000 for net realized pre-tax losses of $545,000 and $1,019,000, respectively. A loss of $5,237,000 and $4,635,000 was recognized in selling, general and administrative (SG&A) expenses for the

Fair Values

Fair Values	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Values Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable. The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Significant Other Significant Other Level I Level II Level III June 30, 2022 Forward exchange contracts—net — $ (2,942) — December 31, 2021 Forward exchange contracts—net — $ (1,552) — The carrying values and fair values of the company’s financial instruments are as follows (in thousands): June 30, 2022 December 31, 2021 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 43,909 $ 43,909 $ 83,745 $ 83,745 Forward contracts in Other current assets 2,058 2,058 386 386 Forward contracts in Accrued expenses (5,000) (5,000) (1,938) (1,938) Total debt (including current maturities of long-term debt) * (313,650) (232,323) (308,129) (259,472) 2022 Notes — — (2,642) (2,632) Series I 2024 Notes (72,274) (63,976) (72,140) (64,897) Series II 2024 Notes (80,248) (68,845) (78,251) (74,165) 2026 Notes (119,745) (58,119) (119,036) (81,718) Other (41,383) (41,383) (36,060) (36,060) ________ * The company's total debt is shown net of fees associated with the convertible senior notes due in 2022, 2024 and 2026 on the company's condensed consolidated balance sheets. Accordingly, the fair values of the convertible senior notes due in 2022, 2024 and 2026 are included in the long-term debt presented in this table are also shown net of fees. Total debt amounts exclude operating and finance lease obligations. The company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions: Cash, cash equivalents: The carrying value reported in the balance sheet for cash, cash equivalents equals its fair value. The fair values are deemed to be categorized as Level 1. Forward Contracts: The company operates internationally, and as a result, is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans and third-party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge the following currencies: AUD, CAD, DKK, EUR, GBP, MXN, NOK, NZD, SEK, THB, and USD. The company does not use derivative financial instruments for speculative purposes. Fair values for the company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities. The fair values are deemed to be categorized as Level 2. The company's forward contracts are included in Other Current Assets or Accrued Expenses in the condensed consolidated balance sheets.

Business Segments

Business Segments	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Business Segments	Business Segments The company operates in two primary business segments: North America and Europe with each selling the company's primary product categories, which include: lifestyle, mobility and seating and respiratory therapy products. Sales in Asia Pacific are reported in All Other and include products similar to those sold in North America and Europe. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company's condensed consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Segment performance is measured and resources are allocated based on a number of factors, with the primary income or loss measure being segment operating income (loss). Segment operating income (loss) represents net sales less cost of products sold less selling general and administrative expenses. Segment operating income (loss) excludes unallocated corporate general and administrative expenses not allocated to the segments and intersegment sales and profit eliminations, which are included in All Other. In addition, segment operating income (loss) further excludes charges related to restructuring activities, asset impairment and gain on sale of business (as applicable). This performance measure, segment operating income (loss), is used by the Chief Operating Decision Maker (CODM) for purposes of making decisions about allocating resources to a segment and assessing its performance. In addition, this metric is reviewed by the company's Board of Directors regarding segment performance and is a key metric in the performance management assessment of the company's employees. The information by segment is as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Revenues from external customers Europe $ 112,768 $ 121,296 $ 230,847 $ 234,071 North America 68,718 96,247 144,037 172,221 All Other (Asia Pacific) 7,531 8,321 15,121 15,774 Consolidated $ 189,017 $ 225,864 $ 390,005 $ 422,066 Intersegment revenues Europe $ 4,129 $ 6,229 $ 8,564 $ 11,537 North America 7,440 16,664 18,536 30,859 Consolidated $ 11,569 $ 22,893 $ 27,100 $ 42,396 Restructuring charges before income taxes Europe $ 2,613 $ 516 $ 4,732 $ 1,246 North America 1,540 31 3,202 853 All Other — — 9 — Consolidated $ 4,153 $ 547 $ 7,943 $ 2,099 Operating income (loss) Europe $ 3,489 $ 4,992 $ 6,714 $ 8,824 North America (6,264) 1,590 (14,600) (785) All Other (7,866) (9,529) (15,590) (15,169) Charges related to restructuring activities (4,153) (547) (7,943) (2,099) Consolidated operating loss (14,794) (3,494) (31,419) (9,229) Loss on debt extinguishment including debt finance charges and associated fees — — — (709) Net interest expense (6,229) (6,084) (12,481) (11,814) Loss before income taxes $ (21,023) $ (9,578) $ (43,900) $ (21,752) Net sales by product, are as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Europe Lifestyle $ 54,997 $ 61,647 $ 116,061 $ 119,945 Mobility and Seating 47,830 51,903 95,232 96,125 Respiratory Therapy 4,922 3,350 9,585 9,388 Other(1) 5,019 4,396 9,969 8,613 $ 112,768 $ 121,296 $ 230,847 $ 234,071 North America Lifestyle $ 33,836 $ 40,100 $ 68,137 $ 76,285 Mobility and Seating 26,001 31,096 51,423 53,829 Respiratory Therapy 8,688 24,789 24,148 41,573 Other(1) 193 262 329 534 $ 68,718 $ 96,247 $ 144,037 $ 172,221 All Other (Asia Pacific) Mobility and Seating $ 2,857 $ 2,850 $ 5,683 $ 6,068 Lifestyle 2,988 2,982 5,678 5,506 Respiratory Therapy 352 1,050 1,131 1,332 Other(1) 1,334 1,439 2,629 2,868 $ 7,531 $ 8,321 $ 15,121 $ 15,774 Total Consolidated $ 189,017 $ 225,864 $ 390,005 $ 422,066 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies General In the ordinary course of its business, the company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All the product liability lawsuits that the company faces in the United States have been referred to the company's captive insurance company and/or excess insurance carriers while all non-U.S. lawsuits have been referred to the company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting, developing, testing, manufacturing, labeling, promoting, distributing and other practices of health care suppliers and medical device manufacturers are all subject to government scrutiny. Most of the company's facilities are subject to inspection at any time by the FDA or similar medical device regulatory agencies in other jurisdictions. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, which could have a material adverse effect on the company's business. Medical Device Regulatory Matters The FDA in the United States and comparable medical device regulatory authorities in other jurisdictions regulate virtually all aspects of the marketing, invoicing, documenting, development, testing, manufacturing, labeling, promotion, distribution and other practices regarding medical devices. The company and its products are subject to the laws and regulations of the FDA and other regulatory bodies in the various jurisdictions where the company's products are manufactured or sold. The company's failure to comply with the regulatory requirements of the FDA and other applicable medical device regulatory requirements can subject the company to administrative or judicially imposed sanctions or enforcement actions. These sanctions include injunctions, consent decrees, warning letters, civil penalties, criminal penalties, product seizure or detention, product recalls and total or partial suspension of production. In December 2012, the company became subject to a consent decree of injunction filed by the FDA with respect to the company's Corporate facility and its Taylor Street manufacturing facility in Elyria, Ohio. The consent decree initially limited the company's (i) manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility ("Taylor Street products") , except in verified cases of medical necessity, (ii) design activities related to wheelchairs and power beds that take place at the impacted Elyria facilities and (iii) replacement, service and repair of products already in use from the Taylor Street manufacturing facility. Under the terms of the consent decree, in order to resume full operations, the company had to successfully complete independent, third-party expert certification audits at the impacted Elyria facilities, comprising three distinct certification reports separately submitted to, and subject to acceptance by, the FDA; submit its own report to the FDA; and successfully complete a reinspection by the FDA of the company's Corporate and Taylor Street facilities. On July 24, 2017, following its June 2017 reinspection of the Corporate and Taylor Street facilities, the FDA notified the company that it was in substantial compliance with the FDA Act, FDA regulations and the terms of the consent decree and, that the company was permitted to resume full operations at those facilities including the resumption of unrestricted sales of products made in those facilities. The consent decree will continue in effect for at least five years from July 24, 2017, during which time the company's Corporate and Taylor Street facilities must complete two semi-annual audits in the first year and then four annual audits in the next four years performed by an independent company-retained audit firm. The expert audit firm will determine whether the facilities remain in continuous compliance with the Federal Food, Drug and Cosmetic Act ("FDA Act"), FDA regulations and the terms of the consent decree and issue post audit reports contemporaneously to the FDA, and the FDA has the authority to inspect these facilities and any other FDA registered facility, at any time. The FDA has continued to actively inspect the company's facilities, other than through the processes established under the consent decree. The company expects that the FDA will, from time to time, inspect substantially all the company's domestic and foreign FDA-registered facilities. In 2021, FDA conducted an inspection of the company’s Corporate and Taylor Street facilities from May 25 through June 24, 2021. At the close of the inspection, six FDA Form 483 observations were issued, and the company timely responded to FDA, has diligently taken actions to address FDA’s inspectional observations, and has provided FDA monthly updates on the corrective actions taken to address these observations. On November 18, 2021, the company received a warning letter from the FDA concerning certain of the inspectional observations in the June 2021 FDA Form 483 related to the complaint handling process, the corrective and preventive action (“CAPA”) process, and medical device reporting (“MDR”) associated with oxygen concentrators (the “Warning Letter”). On November 16, 2021, the company received a consent decree non-compliance letter from the FDA concerning the same complaint and CAPA handling matters as in the Warning Letter observations but associated with the Taylor Street products (this letter, together with the Warning Letter, the “FDA Letters”). The company timely responded to the FDA Letters, has diligently taken actions to address FDA’s concerns, and has provided FDA with periodic updates on the corrective actions taken to address the matters in the FDA Letters. The company remains committed to resolving the FDA’s concerns; however, it is not possible to predict the outcome or timing of a resolution at this time. There can be no assurance that the FDA will be satisfied with the company’s responses to the FDA Letters, nor any assurance as to the timeframe that may be required for the company to adequately address the FDA’s concerns or whether the matters in the FDA Letters will result in an extension in the duration of the consent decree. As of the date of filing of the company’s Quarterly Report on Form 10-Q, there has been no impact on the Company’s ability to produce and market its products as a result of the FDA Letters. Under the consent decree, the FDA has the authority to order the company to take a wide variety of actions if the FDA finds that the company is not in compliance with the consent decree, FDA Act or FDA regulations, including requiring the company to cease all operations relating to Taylor Street products. The FDA also can order the company to undertake a partial cessation of operations or a recall, issue a safety alert, public health advisory, or press release, or to take any other corrective action the FDA deems necessary with respect to Taylor Street products. The FDA also has authority under the consent decree to assess liquidated damages of $15,000 per violation per day for any violations of the consent decree, FDA regulations or the FDA Act. The FDA also may assess liquidated damages for shipments of adulterated or misbranded devices in the amount of twice the sale price of any such adulterated or misbranded device. The liquidated damages, if assessed, are limited to a total of $7,000,000 for each calendar year. The authority to assess liquidated damages is in addition to any other remedies otherwise available to the FDA, including civil money penalties. The results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA Letters, any other FDA warning letters or inspectional observations, or other FDA enforcement related to company facilities, could materially and adversely affect the company's business, financial condition, and results of operations. The limitations previously imposed by the FDA consent decree negatively affected net sales in the North America segment and, to a certain extent, the Asia Pacific region beginning in 2012. The limitations led to delays in new product introductions. Further, uncertainty regarding how long the limitations would be in effect limited the company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. Although the company has been permitted to resume full operations at the Corporate and Taylor Street facilities, the negative effect of the consent decree on customer orders and net sales in the North America segment and Asia Pacific region has been considerable, and it is uncertain as to whether, or how quickly, the company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, when compared to the company's historic results, the previous limitations in the consent decree had, and likely may continue to have, a material adverse effect on the company's business, financial condition and results of operations. Warranty Matters The company's warranty reserves are subject to adjustment in future periods based on historical analysis of warranty claims and as new developments occur that may change the company's estimates related to specific product recalls. Refer to Current Liabilities in the notes to the condensed consolidated financial statements for the total provision amounts and a reconciliation of the changes in the warranty accrual. Any of the above contingencies could have an adverse impact on the company's financial condition or results of operations. For additional information regarding the consent decree, other regulatory matters, and risks and trends that may impact the company’s financial condition or results of operations, please see the following sections of the company's Annual Report on Form 10-K for the year ended December 31, 2021: Item 1. Business - Government Regulation and Item 1A. Risk Factors; Item 3. Legal Proceedings; and Item 7. Management's

Accounting Policies (Policies)

Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation: The condensed consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of June 30, 2022 and the results of its operations and changes in its cash flow for the six months ended June 30, 2022 and 2021, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a May 31 quarter end to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company's financial statements. All significant intercompany transactions are eliminated. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	Use of Estimates: The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements (Already Adopted):
New Accounting Pronouncements, Not yet Adopted	In March 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848): Facilitation of Effects of Reference Rate Reform on Financial Reporting," which is intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burden related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates if certain criteria are met. The guidance may be adopted in any period prior to the guidance expiration on December 31, 2022. The company adopted ASU 2020-04 effective January 1, 2022 and the adoption did not have a material impact on the company's financial statements. Interest arrangements previously referring to LIBOR prior to adoption, now refer to a secured overnight finance rate (SOFR).

Receivables (Tables)

Receivables (Tables)	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Schedule of Accounts Receivable	Receivables consist of the following (in thousands): June 30, 2022 December 31, 2021 Accounts receivable, gross $ 113,612 $ 142,806 Customer rebate reserve (10,696) (12,267) Cash discount reserves (7,746) (9,179) Allowance for doubtful accounts (3,261) (3,642) Other, principally returns and allowances reserves (960) (603) Accounts receivable, net $ 90,949 $ 117,115
Schedule for Allowance for Credit Losses	The movement in the trade receivables allowance for doubtful accounts was as follows (in thousands): Six Ended Balance as of beginning of period $ 3,642 Current period provision 318 Recoveries (direct write-offs), net (699) Balance as of end of period $ 3,261
Schedule of Installment Receivables	Installment receivables consist of the following (in thousands): June 30, 2022 December 31, 2021 Current Long-Term Total Current Long-Term Total Installment receivables $ 284 $ 393 $ 677 $ 218 $ 734 $ 952 Allowance for doubtful accounts — — — — — — Installment receivables, net $ 284 $ 393 $ 677 $ 218 $ 734 $ 952
Schedule of Installment Receivables Allowance for Doubtful Accounts	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): Six Months Ended June 30, 2022 Year Ended December 31, 2021 Balance as of beginning of period $ — $ 487 Current period provision (benefit) — (75) Direct write-offs charged against the allowance — (412) Balance as of end of period $ — $ —
Schedule of Installment Receivables by Class	Installment receivables by class as of June 30, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-Impaired installment receivables with no related allowance recorded 677 677 — — Total Non-Impaired installment receivables with no related allowance recorded 677 677 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 677 $ 677 $ — $ — Installment receivables by class as of December 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 952 952 — — Total Non-impaired installment receivables with no related allowance recorded 952 952 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 952 $ 952 $ — $ —
Schedule of Financing Receivables	Installment receivables by class as of June 30, 2022 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-Impaired installment receivables with no related allowance recorded 677 677 — — Total Non-Impaired installment receivables with no related allowance recorded 677 677 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 677 $ 677 $ — $ — Installment receivables by class as of December 31, 2021 consist of the following (in thousands): Total Unpaid Related Interest Asia Pacific Non-impaired installment receivables with no related allowance recorded 952 952 — — Total Non-impaired installment receivables with no related allowance recorded 952 952 — — Impaired installment receivables with a related allowance recorded — — — — Total installment receivables $ 952 $ 952 $ — $ —
Schedule of Aging of Installment Receivables	The aging of the company’s installment receivables was as follows (in thousands): June 30, 2022 December 31, 2021 Total Asia Pacific Total Asia Pacific Current $ 655 $ 655 $ 952 $ 952 0-30 days past due 22 22 — — 31-60 days past due — — — — 61-90 days past due — — — — 90+ days past due — — — — $ 677 $ 677 $ 952 $ 952

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): June 30, 2022 December 31, 2021 Raw materials $ 65,053 $ 69,371 Finished goods 62,481 62,124 Work in process 11,272 12,779 Inventories, net $ 138,806 $ 144,274

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	Other current assets consist of the following (in thousands): June 30, 2022 December 31, 2021 Tax receivables principally value added taxes $ 26,894 $ 21,943 Prepaid insurance 1,436 4,462 Prepaid inventory and freight 2,138 2,394 Recoverable income taxes 2,205 2,301 Derivatives (foreign currency forward exchange contracts) 2,058 386 Receivable due from information technology provider 898 612 Service contracts 980 304 Deferred financing fees 404 379 Prepaid and other current assets 6,084 7,255 Other Current Assets $ 43,097 $ 40,036

Other Long-Term Assets (Tables)

Other Long-Term Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets, Noncurrent	Other long-term assets consist of the following (in thousands): June 30, 2022 December 31, 2021 Cash surrender value of life insurance policies $ 2,528 $ 2,481 Deferred financing fees 2,052 409 Deferred income taxes 1,535 1,540 Installment receivables 393 734 Investments 85 86 Other 78 112 Other Long-Term Assets $ 6,671 $ 5,362

Property And Equipment (Tables)

Property And Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment consist of the following (in thousands): June 30, 2022 December 31, 2021 Machinery and equipment $ 272,818 $ 278,347 Capitalized software 30,921 30,448 Land, buildings and improvements 25,873 27,299 Furniture and fixtures 8,191 8,943 Leasehold improvements 4,861 6,782 Property and Equipment, gross 342,664 351,819 Accumulated depreciation (286,780) (290,898) Property and Equipment, net $ 55,884 $ 60,921

Intangibles (Tables)

Intangibles (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	The company's intangibles consist of the following (in thousands): June 30, 2022 December 31, 2021 Historical Accumulated Historical Accumulated Customer lists $ 50,078 $ 50,078 $ 52,447 $ 52,447 Trademarks 22,961 — 24,137 — Developed technology 7,342 6,952 7,652 7,149 Patents 5,522 5,522 5,543 5,543 License agreements 4,019 1,300 2,905 1,196 Other 1,149 1,140 1,147 1,140 Intangibles $ 91,071 $ 64,992 $ 93,831 $ 67,475
Schedule of Finite-Lived Intangible Assets	The company's intangibles consist of the following (in thousands): June 30, 2022 December 31, 2021 Historical Accumulated Historical Accumulated Customer lists $ 50,078 $ 50,078 $ 52,447 $ 52,447 Trademarks 22,961 — 24,137 — Developed technology 7,342 6,952 7,652 7,149 Patents 5,522 5,522 5,543 5,543 License agreements 4,019 1,300 2,905 1,196 Other 1,149 1,140 1,147 1,140 Intangibles $ 91,071 $ 64,992 $ 93,831 $ 67,475

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of accruals for the following (in thousands): June 30, 2022 December 31, 2021 Taxes other than income taxes, primarily value added taxes $ 28,628 $ 23,217 Salaries and wages 20,350 24,012 Warranty 9,511 11,198 Professional 9,475 8,697 Freight 6,830 5,460 Derivative liabilities (foreign currency forward exchange contracts) 5,000 1,938 IT service contracts 4,021 4,013 Interest 3,264 3,297 Severance 2,744 400 Product liability, current portion 2,496 2,362 Deferred revenue 2,404 4,156 Rebates 1,062 6,569 Insurance 622 625 Supplemental executive retirement program liability 391 391 Rent 59 196 Other items, principally trade accruals 8,294 6,440 Accrued Expenses $ 105,151 $ 102,971
Schedule of Product Warranty Liability	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands): Balance as of January 1, 2022 $ 11,198 Warranties provided during the period 1,498 Settlements made during the period (3,293) Changes in liability for pre-existing warranties during the period, including expirations 108 Balance as of June 30, 2022 $ 9,511

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt consists of the following (in thousands): June 30, 2022 December 31, 2021 Convertible senior notes at 4.50%, due in June 2022 — 2,642 Convertible senior notes Series I at 5.00%, due in November 2024 72,274 72,140 Convertible senior notes Series II at 5.00%, due November 2024 80,248 78,251 Convertible senior notes at 4.25%, due in March 2026 119,745 119,036 Other obligations 41,383 36,060 313,650 308,129 Less current maturities of long-term debt (2,161) (3,107) Long-Term Debt $ 311,489 $ 305,022
Liability Components of Convertible 2022 Note	The liability components of the 2022 Notes consist of the following (in thousands): June 30, 2022 December 31, 2021 Principal amount of liability component $ — $ 2,650 Debt fees — (8) Net carrying amount of liability component $ — $ 2,642
Liability Components of Convertible 2024 Note	The liability components of the Series I 2024 Notes consist of the following (in thousands): June 30, 2022 December 31, 2021 Principal amount of liability component $ 72,909 $ 72,909 Debt fees (635) (769) Net carrying amount of liability component $ 72,274 $ 72,140
Liability Components of Convertible Series II 2024 Note	The liability components of the Series II 2024 Notes consist of the following (in thousands): June 30, 2022 December 31, 2021 Principal amount of liability component - including accretion $ 81,051 $ 79,222 Debt fees (803) (971) Net carrying amount of liability component $ 80,248 $ 78,251
Liability Components of Convertible 2026 Note	The liability components of the 2026 Notes consist of the following (in thousands): June 30, 2022 December 31, 2021 Principal amount of liability component $ 125,000 $ 125,000 Debt fees (5,255) (5,964) Net carrying amount of liability component $ 119,745 $ 119,036

Other Long-Term Obligations (Ta

Other Long-Term Obligations (Tables)	6 Months Ended
	Jun. 30, 2022
Other Liabilities Disclosure [Abstract]
Other Noncurrent Liabilities	Other long-term obligations consist of the following (in thousands): June 30, 2022 December 31, 2021 Deferred income taxes $ 20,961 $ 21,664 Product liability 11,644 11,342 Deferred compensation 5,384 6,174 Deferred gain on sale leaseback 5,005 5,174 Supplemental executive retirement plan liability 4,833 5,106 Death benefit obligation plan 3,654 4,568 Pension 3,109 7,814 Uncertain tax obligation including interest 3,093 3,171 Other 466 1,783 Other Long-Term Obligations $ 58,149 $ 66,796

Leases and Commitments (Tables)

Leases and Commitments (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lease, Cost [Table]	Lease expenses for the three and six months ended June 30, 2022 and June 30, 2021, respectively, were as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Operating leases $ 1,420 $ 1,819 $ 3,030 $ 3,781 Variable and short-term leases 631 1,010 1,345 2,061 Total operating leases $ 2,051 $ 2,829 $ 4,375 $ 5,842 Finance lease interest cost $ 1,079 $ 1,163 $ 2,162 $ 2,341 Finance lease depreciation 1,063 1,266 2,155 2,542 Total finance leases $ 2,142 $ 2,429 $ 4,317 $ 4,883
Schedule of Cash Flow, Supplemental Disclosures [Table]	Supplemental cash flow amounts for the three and six months ended June 30, 2022 and June 30, 2021 were as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, Cash Activity: Cash paid in measurement of amounts for lease liabilities 2022 2021 2022 2021 Operating leases $ 2,060 $ 2,897 $ 4,299 $ 5,917 Finance leases 1,839 2,102 3,668 4,211 Total $ 3,899 $ 4,999 $ 7,967 $ 10,128 Non-Cash Activity: Right-of-use assets obtained in exchange for lease obligations 2022 2021 2022 2021 Operating leases $ 449 $ 590 $ 1,165 $ 4,429 Finance leases 740 181 915 6,156 Total $ 1,189 $ 771 $ 2,080 $ 10,585
Weighted-Average Remaining Lease Terms and Discount Rates [Table]	Weighted-average remaining lease terms and discount rates for finance and operating leases are as follows as of June 30, 2022 and December 31, 2021, respectively: June 30, 2022 December 31, 2021 Weighted-average remaining lease term - finance leases 15.2 years 15.8 years Weighted-average remaining lease term - operating leases 4.9 years 5.0 years Weighted-average discount rate - finance leases 6.42% 6.43% Weighted-average discount rate - operating leases 7.08% 7.10%
Lessee, Operating Lease, Liability, Maturity	Future minimum operating and finance lease commitments, as of June 30, 2022, are as follows (in thousands): Finance Operating Leases 2022 $ 3,416 $ 2,325 2023 6,772 2,990 2024 6,716 2,254 2025 6,620 1,798 2026 6,508 1,104 Thereafter 68,436 1,634 Total future minimum lease payments 98,468 12,105 Amounts representing interest (34,673) (1,497) Present value of minimum lease payments 63,795 10,608 Less: current maturities of lease obligations (3,085) (3,551) Long-term lease obligations $ 60,710 $ 7,057
Finance Lease, Liability, Fiscal Year Maturity	Future minimum operating and finance lease commitments, as of June 30, 2022, are as follows (in thousands): Finance Operating Leases 2022 $ 3,416 $ 2,325 2023 6,772 2,990 2024 6,716 2,254 2025 6,620 1,798 2026 6,508 1,104 Thereafter 68,436 1,634 Total future minimum lease payments 98,468 12,105 Amounts representing interest (34,673) (1,497) Present value of minimum lease payments 63,795 10,608 Less: current maturities of lease obligations (3,085) (3,551) Long-term lease obligations $ 60,710 $ 7,057

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements	The following tables disaggregate the company’s revenues by major source and by reportable segment for the three and six months ended June 30, 2022 and June 30, 2021 (in thousands): Three Months Ended June 30, 2022 Product Service Total Europe $ 109,479 $ 3,289 $ 112,768 North America 68,525 193 68,718 All Other 6,305 1,226 7,531 Total $ 184,309 $ 4,708 $ 189,017 % Split 98% 2% 100% Six Months Ended June 30, 2022 Product Service Total Europe $ 224,744 $ 6,103 $ 230,847 North America 143,708 329 144,037 All Other 12,687 2,434 15,121 Total $ 381,139 $ 8,866 $ 390,005 % Split 98% 2% 100% Three Months Ended June 30, 2021 Product Service Total Europe $ 118,165 $ 3,131 $ 121,296 North America 95,985 262 96,247 All Other 7,044 1,277 8,321 Total $ 221,194 $ 4,670 $ 225,864 % Split 98% 2% 100% Six Months Ended June 30, 2021 Product Service Total Europe $ 228,009 $ 6,062 $ 234,071 North America 171,687 534 172,221 All Other 13,222 2,552 15,774 Total $ 412,918 $ 9,148 $ 422,066 % Split 98% 2% 100%

Equity Compensation (Tables)

Equity Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The amounts of equity-based compensation expense recognized as part of SG&A expenses in All Other in business segment reporting were as follows (in thousands): For the Six Months Ended June 30, 2022 2021 Restricted stock and restricted stock units $ 2,597 $ 3,761 Performance shares and performance share units (319) 2,049 Total stock-based compensation expense $ 2,278 $ 5,810
Schedule of Unrecognized Compensation Cost, Nonvested Awards	As of June 30, 2022, unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2018 Plan and previous plans, which is related to non-vested awards, was as follows (in thousands): June 30, 2022 Restricted stock and restricted stock units $ 4,864 Performance shares and performance share units 1,354 Total unrecognized stock-based compensation expense $ 6,218
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes information about stock option activity for the six months ended June 30, 2022: Weighted Average Options outstanding at January 1, 2022 750,159 $ 12.69 Expired (3,000) 17.47 Options outstanding at June 30, 2022 747,159 $ 12.67 Options exercise price range at June 30, 2022 $ 12.15 to $ 14.49 Options exercisable at June 30, 2022 747,159 Shares available for grant under the 2018 Plan at June 30, 2022* 2,362,474 ________
Schedule of Share-based Compensation, Stock Options Outstanding	The following table summarizes information about stock options outstanding at June 30, 2022: Options Outstanding Options Exercisable Exercise Prices Number Weighted Average Weighted Average Number Exercisable at Weighted Average $12.15 – $20.00 747,159 3.5 $ 12.67 747,159 $ 12.67
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes information about restricted stock and restricted stock units (primarily for non-U.S. recipients): Weighted Average Fair Value Stock / Units unvested at January 1, 2022 1,160,847 $ 8.17 Granted 1,017,055 1.48 Vested (549,774) 8.43 Forfeited (131,256) 6.94 Stock / Units unvested at 1,496,872 $ 3.64
Share-based Compensation, Performance Shares Award Unvested Activity	The following table summarizes information about performance shares and performance share units (primarily for non-U.S. recipients): Weighted Average Fair Value Shares / Units unvested at January 1, 2022 972,288 $ 7.76 Granted 460,187 1.48 Shares / Units unvested at 1,432,475 $ 5.75

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) by Component (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) ("OCI") (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total March 31, 2022 $ 12,193 $ 2,553 $ (3,877) $ 825 $ 11,694 OCI before reclassifications (25,540) (1,005) 4,299 1,263 (20,983) Amount reclassified from accumulated OCI — — 40 (635) (595) Net current-period OCI (25,540) (1,005) 4,339 628 (21,578) June 30, 2022 $ (13,347) $ 1,548 $ 462 $ 1,453 $ (9,884) Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2021 $ 18,961 $ 2,127 $ (4,101) $ 1 $ 16,988 OCI before reclassifications (32,308) (579) 4,617 2,138 (26,132) Amount reclassified from accumulated OCI — — (54) (686) (740) Net current-period OCI (32,308) (579) 4,563 1,452 (26,872) June 30, 2022 $ (13,347) $ 1,548 $ 462 $ 1,453 $ (9,884) Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total March 31, 2021 $ 53,131 $ 2,358 $ (3,325) $ (1,494) $ 50,670 OCI before reclassifications 7,250 (212) (701) (369) 5,968 Amount reclassified from accumulated OCI — — (43) 484 441 Net current-period OCI 7,250 (212) (744) 115 6,409 June 30, 2021 $ 60,381 $ 2,146 $ (4,069) $ (1,379) $ 57,079 Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2020 $ 50,329 $ (517) $ (3,674) $ (702) $ 45,436 OCI before reclassifications 10,052 2,663 (231) (1,587) 10,897 Amount reclassified from accumulated OCI — — (164) 910 746 Net current-period OCI 10,052 2,663 (395) (677) 11,643 June 30, 2021 $ 60,381 $ 2,146 $ (4,069) $ (1,379) $ 57,079
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	Reclassifications out of accumulated OCI were as follows (in thousands): Amount reclassified from OCI Amount reclassified from OCI Affected line item in the Statement of Comprehensive (Income) Loss For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Defined Benefit Plans Service and interest costs $ 40 $ (43) $ (54) $ (164) Selling, general and administrative expenses Tax — — — — Income taxes Total after tax $ 40 $ (43) $ (54) $ (164) Derivatives Foreign currency forward contracts hedging sales $ (30) $ 159 $ (57) $ 181 Net sales Foreign currency forward contracts hedging purchases (703) 386 (734) 838 Cost of products sold Total loss (income) before tax (733) 545 (791) 1,019 Tax 98 (61) 105 (109) Income taxes Total after tax $ (635) $ 484 $ (686) $ 910

Charges Related To Restructur_2

Charges Related To Restructuring Activities (Tables)	6 Months Ended
	Jun. 30, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	A progression by reporting segment of the accruals recorded as a result of the restructuring for the six months ended June 30, 2022 is as follows (in thousands): Severance Other Total December 31, 2021 Balances North America $ 482 $ — $ 482 Total 482 — 482 Charges North America 1,124 538 1,662 Europe 2,119 — 2,119 All Other 9 9 Total 3,252 538 3,790 Payments North America (422) (538) (960) Europe (367) — (367) All Other (9) — (9) Total (798) (538) (1,336) March 31, 2022 Balances North America 1,184 — 1,184 Europe 1,752 — 1,752 Total $ 2,936 $ — $ 2,936 Charges North America $ 542 998 $ 1,540 Europe 1,288 1,325 2,613 Total 1,830 2,323 4,153 Payments North America (768) (442) (1,210) Europe (1,254) (624) (1,878) Total (2,022) (1,066) (3,088) June 30, 2022 Balances North America 958 556 1,514 Europe 1,786 701 2,487 Total $ 2,744 $ 1,257 $ 4,001

Net Earnings (Loss) Per Commo_2

Net Earnings (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated. (In thousands except per share data) For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Basic Weighted average common shares outstanding 35,634 34,969 35,340 34,732 Net loss $ (21,943) $ (10,698) $ (46,140) $ (24,742) Net loss per common share $ (0.62) $ (0.31) $ (1.31) $ (0.71) Diluted Weighted average common shares outstanding 35,634 34,969 35,340 34,732 Share options and awards 361 651 374 718 Weighted average common shares assuming dilution 35,995 35,620 35,714 35,450 Net loss $ (21,943) $ (10,698) $ (46,140) $ (24,742) Net loss per common share * $ (0.62) $ (0.31) $ (1.31) $ (0.71) ________ * Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): June 30, 2022 December 31, 2021 Notional Unrealized Notional Unrealized USD / EUR 23,147 1,452 — — USD / CAD 11,750 (49) — — EUR / GBP 9,353 181 — — EUR / NOK 3,932 19 — — NOK / SEK 2,313 (16) — — USD / MXN 2,209 106 23 1 $ 52,704 $ 1,693 $ 23 $ 1
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment, as well as ineffective hedges, entered into in 2022 and 2021, respectively, and outstanding were as follows (in thousands USD): June 30, 2022 December 31, 2021 Notional Gain Notional Gain USD / AUD $ 1,299 $ 1 $ 3,792 $ (57) USD / CAD 19,084 (10) 14,556 (24) USD / EUR 80,306 (2,954) 70,454 (1,104) USD / DKK 12,352 (714) 10,850 (257) USD / GBP 3,717 (63) 4,028 32 USD / NOK 5,352 (579) 2,352 (81) USD / SEK 2,152 (196) 2,344 (131) EUR / GBP 5,928 115 — — EUR / NOK 5 — — — AUD / NZD 7,517 (36) 7,366 (17) USD / THB 4,270 (46) 4,500 86 EUR / SEK 6,797 (153) — — $ 148,779 $ (4,635) $ 120,242 $ (1,553)
Schedule of Derivatives Instruments Statements of Financial Position, Fair Value	The fair values of the company’s derivative instruments were as follows (in thousands): June 30, 2022 December 31, 2021 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ 1,782 $ 89 $ 1 $ — Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 276 4,911 385 1,938 Total derivatives $ 2,058 $ 5,000 $ 386 $ 1,938
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)	The effect of derivative instruments on Accumulated Other Comprehensive Income (Loss) (OCI) and the condensed consolidated Statements of comprehensive income (loss) was as follows (in thousands): Derivatives (foreign currency forward exchange contracts) in ASC 815 cash flow hedge Amount of Gain Amount of Gain (Loss) Amount of Gain (Loss) Three months ended June 30, 2022 Foreign currency forward exchange contracts $ 1,263 $ 635 $ 115 Six months ended June 30, 2022 Foreign currency forward exchange contracts $ 2,138 $ 686 $ 115 Three months ended June 30, 2021 Foreign currency forward exchange contracts $ (369) $ (484) $ (88) Six months ended June 30, 2021 Foreign currency forward exchange contracts $ (1,587) $ (910) $ (88) Derivatives (foreign currency forward exchange contracts) not designated as hedging Amount of Gain (Loss) Three months ended June 30, 2022 Foreign currency forward exchange contracts $ (5,237) Six months ended June 30, 2022 Foreign currency forward exchange contracts $ (4,635) Three months ended June 30, 2021 Foreign currency forward exchange contracts $ 264 Six months ended June 30, 2021 Foreign currency forward exchange contracts $ (723)

Fair Values (Tables)

Fair Values (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands): Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Significant Other Significant Other Level I Level II Level III June 30, 2022 Forward exchange contracts—net — $ (2,942) — December 31, 2021 Forward exchange contracts—net — $ (1,552) —
Fair Value, by Balance Sheet Grouping	The carrying values and fair values of the company’s financial instruments are as follows (in thousands): June 30, 2022 December 31, 2021 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 43,909 $ 43,909 $ 83,745 $ 83,745 Forward contracts in Other current assets 2,058 2,058 386 386 Forward contracts in Accrued expenses (5,000) (5,000) (1,938) (1,938) Total debt (including current maturities of long-term debt) * (313,650) (232,323) (308,129) (259,472) 2022 Notes — — (2,642) (2,632) Series I 2024 Notes (72,274) (63,976) (72,140) (64,897) Series II 2024 Notes (80,248) (68,845) (78,251) (74,165) 2026 Notes (119,745) (58,119) (119,036) (81,718) Other (41,383) (41,383) (36,060) (36,060) ________ * The company's total debt is shown net of fees associated with the convertible senior notes due in 2022, 2024 and 2026 on the company's condensed consolidated balance sheets. Accordingly, the fair values of the convertible senior notes due in 2022, 2024 and 2026 are included in the long-term debt presented in this table are also shown net of fees. Total debt amounts exclude operating and finance lease obligations.

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The information by segment is as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Revenues from external customers Europe $ 112,768 $ 121,296 $ 230,847 $ 234,071 North America 68,718 96,247 144,037 172,221 All Other (Asia Pacific) 7,531 8,321 15,121 15,774 Consolidated $ 189,017 $ 225,864 $ 390,005 $ 422,066 Intersegment revenues Europe $ 4,129 $ 6,229 $ 8,564 $ 11,537 North America 7,440 16,664 18,536 30,859 Consolidated $ 11,569 $ 22,893 $ 27,100 $ 42,396 Restructuring charges before income taxes Europe $ 2,613 $ 516 $ 4,732 $ 1,246 North America 1,540 31 3,202 853 All Other — — 9 — Consolidated $ 4,153 $ 547 $ 7,943 $ 2,099 Operating income (loss) Europe $ 3,489 $ 4,992 $ 6,714 $ 8,824 North America (6,264) 1,590 (14,600) (785) All Other (7,866) (9,529) (15,590) (15,169) Charges related to restructuring activities (4,153) (547) (7,943) (2,099) Consolidated operating loss (14,794) (3,494) (31,419) (9,229) Loss on debt extinguishment including debt finance charges and associated fees — — — (709) Net interest expense (6,229) (6,084) (12,481) (11,814) Loss before income taxes $ (21,023) $ (9,578) $ (43,900) $ (21,752)
Revenue from External Customer [Line Items]
Revenue from External Customers by Products and Services [Table Text Block]	Net sales by product, are as follows (in thousands): For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Europe Lifestyle $ 54,997 $ 61,647 $ 116,061 $ 119,945 Mobility and Seating 47,830 51,903 95,232 96,125 Respiratory Therapy 4,922 3,350 9,585 9,388 Other(1) 5,019 4,396 9,969 8,613 $ 112,768 $ 121,296 $ 230,847 $ 234,071 North America Lifestyle $ 33,836 $ 40,100 $ 68,137 $ 76,285 Mobility and Seating 26,001 31,096 51,423 53,829 Respiratory Therapy 8,688 24,789 24,148 41,573 Other(1) 193 262 329 534 $ 68,718 $ 96,247 $ 144,037 $ 172,221 All Other (Asia Pacific) Mobility and Seating $ 2,857 $ 2,850 $ 5,683 $ 6,068 Lifestyle 2,988 2,982 5,678 5,506 Respiratory Therapy 352 1,050 1,131 1,332 Other(1) 1,334 1,439 2,629 2,868 $ 7,531 $ 8,321 $ 15,121 $ 15,774 Total Consolidated $ 189,017 $ 225,864 $ 390,005 $ 422,066 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Receivables (Narrative) (Detail

Receivables (Narrative) (Details)	6 Months Ended
	Jun. 30, 2022 USD ($) payment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Contingent Liability, Guarantee	$ 302,000
Number of missed payments before delinquent | payment	3
Credit amount requiring additional analysis	$ 250,000
Average period of adjudication	18 months
Risk Level, Low
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, North America excluding Canada	1%
Receivables, Expected Loss Percentage, Canada	0.10%
Receivables, Expected Loss Percentage, Europe	0.30%
Receivables, Expected Loss Percentage, AsiaPac	1%
Risk Level, Medium
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	0.90%
Risk Level, High
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables, Expected Loss Percentage, Canada	3.40%

Receivables (Schedule of Accoun

Receivables (Schedule of Accounts Receivable) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule of Accounts Receivable [Abstract]
Accounts receivable, gross	$ 113,612	$ 142,806
Customer rebate reserve	(10,696)	(12,267)
Cash discount reserves	(7,746)	(9,179)
Allowance for doubtful accounts	(3,261)	(3,642)
Other, principally returns and allowances reserves	(960)	(603)
Accounts Receivable, Net	$ 90,949	$ 117,115

Receivables Schedule for Allowa

Receivables Schedule for Allowance for Credit Losses (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Financing Receivable, Allowance for Credit Losses [Line Items]
Allowance for Credit Losses	$ 3,261	$ 3,642
Allowance for Loan and Lease Losses, Adjustments, Other	318
Financing Receivable, Allowance for Credit Losses, Write-downs	$ 699

Receivables (Installment Receva

Receivables (Installment Recevables) (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Receivables [Abstract]
Non-Impaired Financing Receivable, Related Allowance	$ 0	$ 0
Installment Receivables, Current	284,000	218,000
Installment Receivables, Long-Term	393,000	734,000
Total Installment Receivables	677,000	952,000
Total Unearned Interest	(2,404,000)	(4,156,000)
Allowance for doubtful accounts, current	0	0
Allowance for doubtful accounts, long-term	0	0
Allowance for doubtful accounts	0	0	$ (487,000)
Installment receivables, net	284,000	218,000
Installment receivables, net, long-term	393,000	734,000
Installment receivables, net	$ 677,000	$ 952,000

Receivables (Rollforward of All

Receivables (Rollforward of Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Allowance for Doubtful Accounts [Roll Forward]
Balance as of beginning of period	$ 0	$ 487
Current period provision (benefit)	0	(75)
Direct write-offs charged against the allowance	0	(412)
Balance as of end of period	$ 0	$ 0

Receivables (Installment Receiv

Receivables (Installment Receivables by Class) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Total Installment Receivables
Non-Impaired installment receivables with no related allowance recorded	$ 677	$ 952
Impaired installment receivables with a related allowance recorded	0	0
Total installment receivables	677	952
Unpaid Principal Balance
Impaired installment receivables with a related allowance recorded	0	0
Non-Impaired installment receivables with no related allowance recorded	677	952
Total installment receivables	677	952
Non-Impaired Financing Receivable, Related Allowance	0	0
Related Allowance for Doubtful Accounts
Impaired Financing Receivable, Related Allowance	0	0
Interest Income Recognized
Non-Impaired installment receivables with no related allowance recorded	0	0
Impaired Financing Receivable, with Related Allowance, Interest Income, Accrual Method	0	0
Total installment receivables	0	0
All Other
Total Installment Receivables
Non-Impaired installment receivables with no related allowance recorded	677	952
Unpaid Principal Balance
Non-Impaired installment receivables with no related allowance recorded	677	952
Non-Impaired Financing Receivable, Related Allowance	0	0
Interest Income Recognized
Non-Impaired installment receivables with no related allowance recorded	$ 0	$ 0

Receivables (Aging of Installme

Receivables (Aging of Installment Receivables) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Financing Receivable, Recorded Investment, Past Due [Line Items]
0-30 days past due	$ 22	$ 0
31-60 days past due	0	0
61-90 days past due	0	0
90+ days past due	0	0
Installment Receivable, Not Past Due	655	952
Financing Receivable, Gross	677	952
All Other
Financing Receivable, Recorded Investment, Past Due [Line Items]
0-30 days past due	22	0
31-60 days past due	0	0
61-90 days past due	0	0
90+ days past due	0	0
Installment Receivable, Not Past Due	655	952
Financing Receivable, Gross	$ 677	$ 952

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 62,481	$ 62,124
Raw materials	65,053	69,371
Work in process	11,272	12,779
Inventories, net	$ 138,806	$ 144,274

Other Current Assets Components

Other Current Assets Components of Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Tax receivables principally value added taxes	$ 26,894	$ 21,943
Prepaid inventory and freight	2,138	2,394
Receivable due from information technology provider	898	612
Prepaid insurance	1,436	4,462
Derivatives (foreign currency forward exchange contracts)	2,058	386
Recoverable income taxes	2,205	2,301
Service contracts	980	304
Deferred financing fees	404	379
Prepaid and other current assets	6,084	7,255
Other current assets	$ 43,097	$ 40,036

Other Long-Term Assets Componen

Other Long-Term Assets Components of Other Long-Term Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Cash surrender value of life insurance policies	$ 2,528	$ 2,481
Deferred income taxes	1,535	1,540
Installment receivables	393	734
Deferred financing fees	2,052	409
Investments	85	86
Other	78	112
Other Long-Term Assets	$ 6,671	$ 5,362

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 342,664,000		$ 342,664,000		$ 351,819,000
Less allowance for depreciation	(286,780,000)		(286,780,000)		(290,898,000)
Property and equipment, net	55,884,000		55,884,000		60,921,000
Capitalized Computer Software, Net	27,680,000		27,680,000		28,715,000
Computer Software Depreciation Expense	833,000	$ 413,000	1,510,000	$ 665,000
Unpaid Purchases of Property and Equipment	0		0		1,090,000
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	272,818,000		272,818,000		278,347,000
Land, buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	25,873,000		25,873,000		27,299,000
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,191,000		8,191,000		8,943,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,861,000		4,861,000		6,782,000
Capitalized Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 30,921,000		$ 30,921,000		$ 30,448,000

Intangibles (Narrative) (Detail

Intangibles (Narrative) (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 207,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	8 years
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, useful life	6 years

Intangibles (Intangible Table)

Intangibles (Intangible Table) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 91,071	$ 93,831
Accumulated Amortization	64,992	67,475
Customer lists
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	50,078	52,447
Accumulated Amortization	50,078	52,447
Developed technology
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	7,342	7,652
Accumulated Amortization	6,952	7,149
Patents
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	5,522	5,543
Accumulated Amortization	5,522	5,543
License agreements
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	4,019	2,905
Accumulated Amortization	1,300	1,196
Other
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	1,149	1,147
Accumulated Amortization	1,140	1,140
Trademarks
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 22,961	$ 24,137

Intangibles (Finite-Lived Intan

Intangibles (Finite-Lived Intangible Asset Future Amortization Expense) (Details)	Jun. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Future amortization expense, remainder of fiscal year	$ 604,000
Future amortization expense, 2022	619,000
Future amortization expense, 2023	473,000
Future amortization expense, 2024	439,000
Future amortization expense, 2025	437,000
Future amortization expense, 2026	$ 311,000

Accrued Expenses Components of

Accrued Expenses Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Taxes other than income taxes, primarily value added taxes	$ 28,628	$ 23,217
Salaries and wages	20,350	24,012
Warranty	9,511	11,198
Professional	9,475	8,697
Freight	6,830	5,460
Interest	3,264	3,297
IT service contracts	4,021	4,013
Deferred revenue	2,404	4,156
Severance	2,744	400
Rebates	1,062	6,569
Product liability, current portion	2,496	2,362
Derivative liabilities (foreign currency forward exchange contracts)	5,000	1,938
Insurance	622	625
Supplemental executive retirement program liability	391	391
Rent	59	196
Other items, principally trade accruals	8,294	6,440
Accrued expenses	$ 105,151	$ 102,971

Accrued Expenses Warranty Sched

Accrued Expenses Warranty Schedule (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Product Liability Contingency
Balance as of January 1, 2022	$ 11,198
Warranties provided during the period	1,498
Settlements made during the period	(3,293)
Changes in liability for pre-existing warranties during the period, including expirations	108
Balance as of June 30, 2022	$ 9,511

Long-Term Debt (Details)

Long-Term Debt (Details)	3 Months Ended					6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 11, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2017 USD ($)	Jun. 30, 2017 USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 313,650,000					$ 313,650,000		$ 308,129,000
Long-term Debt and Capital Lease Obligations, Current	(2,161,000)					(2,161,000)		(3,107,000)
Long-term debt net of current maturities	311,489,000					311,489,000		305,022,000
Accretion Expense	$ 917,000	$ 877,000				$ 1,828,000	$ 1,747,000
Accretion Rate	4.70%					4.70%
Loss on debt extinguishment including debt finance charges and fees	$ 0	0				$ 0	(709,000)
Purchases of capped calls			$ 18,787,000			$ 0	18,787,000
Cap Price of Capped Call Transaction | $ / shares	$ 16.58					$ 16.58
Lifetime to date - Accretion Expense						$ 7,175,000
Remaining Accretion	$ 9,447,000					9,447,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Debt Instrument [Line Items]
Debt Instrument Exchange Amount				$ 35,375,000	$ 72,909,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	72,909,000					72,909,000		72,909,000
Debt Instrument, Fee Amount	(635,000)					(635,000)		(769,000)
Debt Instrument, Net Carrying Amount	$ 72,274,000					$ 72,274,000		72,140,000
Interest rate (as a percent)	5%					5%
Debt Instrument Repurchase Amount, Cash Paid					6,928,000
Debt Instrument, Increase, Accrued Interest	$ 912,000	911,000				$ 1,823,000	1,822,000
Percent of the Applicable Conversion Price	130%					130%
Last Reported Sales Price Period, Common Stock						20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days						30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%					100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000					$ 1,000
Business Day Period						5 years
Percent of the Product of the Last Reported Sale Price, Common Shares	98%					98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	67.6819					67.6819
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 14.78					$ 14.78
Debt Instrument, Loss on Exchange					5,885,000
Debt Instrument, Fee Amount					$ 1,394,000
Debt Instrument, Interest Rate, Effective Percentage	540%					540%
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	8.80%					8.80%
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 81,051,000					$ 81,051,000		79,222,000
Debt Instrument, Fee Amount	(803,000)					(803,000)		(971,000)
Debt Instrument, Net Carrying Amount	$ 80,248,000					$ 80,248,000		78,251,000
Interest rate (as a percent)	5%					5%
Debt Instrument Repurchase Amount, Cash Paid										$ 5,593,000
Debt Instrument Exchange Amount				73,875,000
Debt Instrument, Increase, Accrued Interest	$ 924,000	924,000				$ 1,847,000	1,847,000
Percent of the Applicable Conversion Price	130%					130%
Last Reported Sales Price Period, Common Stock						20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days						30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%					100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000					$ 1,000
Debt Instrument, Convertible, Threshold Trading Days						10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%					98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	67.6819					67.6819
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 14.78					$ 14.78
Debt Instrument, Loss on Exchange			709,000	6,599,000
Debt Instrument, Fee Amount										$ 1,505,000
Debt Instrument, Interest Rate, Effective Percentage	10.40%					10.40%
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	9%					9%
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 125,000,000					$ 125,000,000		125,000,000
Debt Instrument, Fee Amount	(5,255,000)					(5,255,000)		(5,964,000)
Debt Instrument, Net Carrying Amount	$ 119,745,000					$ 119,745,000		119,036,000
Interest rate (as a percent)	4.25%					4.25%
Debt Instrument, Increase, Accrued Interest	$ 1,328,000	1,328,000				$ 2,656,000	1,564,000
Percent of the Applicable Conversion Price	130%					130%
Last Reported Sales Price Period, Common Stock						20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days						30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%					100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000					$ 1,000
Business Day Period						5 days
Debt Instrument, Convertible, Threshold Trading Days						10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%					98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	94.6096					94.6096
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 10.57					$ 10.57
Debt Instrument, Fee Amount									$ 7,305,000
Capped Call Options, Outstanding	125,000					125,000
Debt Instrument, Interest Rate, Effective Percentage	5.40%					5.40%
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022
Debt Instrument [Line Items]
Debt Instrument, Repurchase Amount			$ 78,850,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 0					$ 0		2,650,000				$ 120,000,000
Long-term debt	0					0		2,642,000
Debt Instrument, Fee Amount	0					0		(8,000)
Debt Instrument, Net Carrying Amount	$ 0					$ 0		2,642,000
Interest rate (as a percent)	4.50%					4.50%
Debt Instrument Repurchase Amount, Cash Paid	$ 2,650,000					$ 2,650,000
Debt Instrument Exchange Amount				$ 38,500,000
Debt Instrument, Increase, Accrued Interest	$ 20,000	$ 30,000				$ 50,000	$ 799,000
Percent of the Applicable Conversion Price	130%					130%
Last Reported Sales Price Period, Common Stock						20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days						30
Convertible Senior Notes, Percentage of Principal Required for Repurchase	100%					100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal	$ 1,000					$ 1,000
Business Day Period						5 years
Debt Instrument, Convertible, Threshold Trading Days						10
Percent of the Product of the Last Reported Sale Price, Common Shares	98%					98%
Convertible Preferred Stock, Shares Issued upon Conversion | shares	61.6095					61.6095
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 16.23					$ 16.23
Debt Instrument, Fee Amount											$ 4,711,000
Class of Warrant or Right, Outstanding | shares	7,393,141					7,393,141
Debt Instrument, Interest Rate, Effective Percentage	5.40%					5.40%
Debt Instrument, Interest Rate on Liability Component, Effective Percentage	10.90%					10.90%
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Long-term debt	$ 72,274,000					$ 72,274,000		72,140,000
Debt Instrument, Convertible, Threshold Trading Days						10
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Long-term debt	80,248,000					$ 80,248,000		78,251,000
Business Day Period						5 years
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount									$ 125,000,000
Long-term debt	$ 119,745,000					$ 119,745,000		119,036,000
Interest rate (as a percent)	4.25%					4.25%
Other Notes and Capital Lease Obligations
Debt Instrument [Line Items]
Long-term debt	$ 41,383,000					$ 41,383,000		36,060,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding	25,950,000					25,950,000		22,150,000
Line of Credit Facility, Covenant Feature, Dominion Trigger	7,500,000					7,500,000
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)	8,803,000					8,803,000		7,366,000
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)	4,412,000					4,412,000		5,986,000
Line Of Credit Facility Gross Borrowing Base	$ 41,324,000					$ 41,324,000
Minimum required undrawn balance (as a percent)	11.25%					11.25%
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | Euro Member Countries, Euro
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)	$ 8,200,000					$ 8,200,000		6,500,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | United Kingdom, Pounds
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)	$ 3,500,000					$ 3,500,000		$ 4,500,000
Senior secured revolving credit facility, due in October 2015 | Line of Credit | Revolving Credit and Security Agreement (North America Credit Agreement)
Debt Instrument [Line Items]
Minimum required undrawn balance (as a percent)	12.50%					12.50%

Long-Term Debt Components of Co

Long-Term Debt Components of Convertible Debt (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2019	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 313,650,000			$ 313,650,000		$ 308,129,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Increase, Accrued Interest	912,000	$ 911,000		1,823,000	$ 1,822,000
Debt Instrument, Loss on Exchange			$ 5,885,000
Debt Instrument, Face Amount	$ 72,909,000			$ 72,909,000		72,909,000
Interest rate (as a percent)	5%			5%
Debt fees	$ (635,000)			$ (635,000)		(769,000)
Debt Instrument, Net Carrying Amount	$ 72,274,000			$ 72,274,000		$ 72,140,000

Long-Term Debt Narrative (Detai

Long-Term Debt Narrative (Details)	3 Months Ended							6 Months Ended		12 Months Ended
	Sep. 30, 2022 USD ($) d shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2017 USD ($) $ / shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2019 USD ($)	Jul. 26, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Mar. 11, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Payments for Repurchase of Common Stock								$ 151,000	$ 1,752,000
Amortization of debt fees								1,230,000	1,035,000
Loss on debt extinguishment including debt finance charges and fees		$ 0	$ 0					0	709,000
Cash surrender value of life insurance policies		2,528,000						2,528,000				$ 2,481,000
Borrowing against Cash Surrender Value of Life Insurance		$ 2,000,000						2,000,000
Purchases of capped calls				$ 18,787,000				$ 0	18,787,000
Cap Price of Capped Call Transaction | $ / shares		$ 16.58						$ 16.58
Accretion Expense		$ 917,000	877,000					$ 1,828,000	1,747,000
Accretion Rate		4.70%						4.70%
Lifetime to date - Accretion Expense								$ 7,175,000
Remaining Accretion		$ 9,447,000						9,447,000
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Fee Amount						$ 1,394,000				$ 1,394,000
Debt Instrument, Face Amount		$ 72,909,000						$ 72,909,000				72,909,000
Interest rate (as a percent)		5%						5%
Debt Instrument Repurchase Amount, Cash Paid						6,928,000				6,928,000
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Percent of the Applicable Conversion Price		130%						130%
Business Day Period								5 years
Percent of the Product of the Last Reported Sale Price, Common Shares		98%						98%
Convertible Senior Notes, Percentage of Principal Required for Repurchase		100%						100%
Convertible Preferred Stock, Shares Issued upon Conversion | shares		67.6819						67.6819
Convertible Debt, Conversion Rate of Commmon Shares, Principal		$ 1,000						$ 1,000
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 14.78						$ 14.78
Debt Instrument, Net Carrying Amount		$ 72,274,000						$ 72,274,000				72,140,000
Debt Instrument, Fee Amount		$ (635,000)						$ (635,000)				(769,000)
Debt Instrument, Interest Rate, Effective Percentage		540%						540%
Debt Instrument, Increase, Accrued Interest		$ 912,000	911,000					$ 1,823,000	1,822,000
Debt Instrument, Loss on Exchange						5,885,000
Debt Instrument, Interest Rate on Liability Component, Effective Percentage		8.80%						8.80%
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% February 2021
Debt Instrument [Line Items]
Debt Instrument Exchange Amount					$ 35,375,000	$ 72,909,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024
Debt Instrument [Line Items]
Debt Instrument, Fee Amount														$ 1,505,000
Debt Instrument, Face Amount		$ 81,051,000						$ 81,051,000				79,222,000
Interest rate (as a percent)		5%						5%
Debt Instrument Exchange Amount					73,875,000
Debt Instrument Repurchase Amount, Cash Paid														$ 5,593,000
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Percent of the Applicable Conversion Price		130%						130%
Debt Instrument, Convertible, Threshold Trading Days								10
Percent of the Product of the Last Reported Sale Price, Common Shares		98%						98%
Convertible Senior Notes, Percentage of Principal Required for Repurchase		100%						100%
Convertible Preferred Stock, Shares Issued upon Conversion | shares		67.6819						67.6819
Convertible Debt, Conversion Rate of Commmon Shares, Principal		$ 1,000						$ 1,000
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 14.78						$ 14.78
Debt Instrument, Net Carrying Amount		$ 80,248,000						$ 80,248,000				78,251,000
Debt Instrument, Fee Amount		$ (803,000)						$ (803,000)				(971,000)
Debt Instrument, Interest Rate, Effective Percentage		10.40%						10.40%
Debt Instrument, Increase, Accrued Interest		$ 924,000	924,000					$ 1,847,000	1,847,000
Debt Instrument, Loss on Exchange				709,000	6,599,000
Debt Instrument, Interest Rate on Liability Component, Effective Percentage		9%						9%
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024 | Subsequent Event
Debt Instrument [Line Items]
Interest rate (as a percent)											5%
Debt Instrument Exchange Amount	$ 5,000,000
Debt Instrument, Amount Outstanding											$ 68,875,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026
Debt Instrument [Line Items]
Debt Instrument, Fee Amount													$ 7,305,000
Debt Instrument, Face Amount		$ 125,000,000						$ 125,000,000				125,000,000
Interest rate (as a percent)		4.25%						4.25%
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Percent of the Applicable Conversion Price		130%						130%
Business Day Period								5 days
Debt Instrument, Convertible, Threshold Trading Days								10
Percent of the Product of the Last Reported Sale Price, Common Shares		98%						98%
Convertible Senior Notes, Percentage of Principal Required for Repurchase		100%						100%
Convertible Preferred Stock, Shares Issued upon Conversion | shares		94.6096						94.6096
Convertible Debt, Conversion Rate of Commmon Shares, Principal		$ 1,000						$ 1,000
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 10.57						$ 10.57
Debt Instrument, Net Carrying Amount		$ 119,745,000						$ 119,745,000				119,036,000
Debt Instrument, Fee Amount		$ (5,255,000)						$ (5,255,000)				(5,964,000)
Debt Instrument, Interest Rate, Effective Percentage		5.40%						5.40%
Debt Instrument, Increase, Accrued Interest		$ 1,328,000	1,328,000					$ 2,656,000	1,564,000
Capped Call Options, Outstanding		125,000						125,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 | Subsequent Event
Debt Instrument [Line Items]
Interest rate (as a percent)											4.25%
Debt Instrument Exchange Amount	55,300,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 | Subsequent Event | Round 1 funding (Initial closing) [Domain]
Debt Instrument [Line Items]
Debt Instrument Exchange Amount	$ 41,475,000
Convertible Subordinated Debt | Convertible Senior Secured Notes at 5.68% July 2026 | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Consecutive Trading Days | d	30
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount													$ 125,000,000
Interest rate (as a percent)		4.25%						4.25%
Convertible Subordinated Debt | Convertible Senior Notes at 4.25% March 2026 [Domain] | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Amount Outstanding											$ 83,525,000
Convertible Subordinated Debt | Series II Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Business Day Period								5 years
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Fee Amount															$ 4,711,000
Debt Instrument, Face Amount		$ 0					$ 120,000,000	$ 0				2,650,000
Interest rate (as a percent)		4.50%						4.50%
Debt Instrument Exchange Amount					$ 38,500,000
Debt Instrument Repurchase Amount, Cash Paid		$ 2,650,000						$ 2,650,000
Last Reported Sales Price Period, Common Stock								20 days
Debt Instrument, Convertible, Threshold Consecutive Trading Days								30
Percent of the Applicable Conversion Price		130%						130%
Business Day Period								5 years
Debt Instrument, Convertible, Threshold Trading Days								10
Percent of the Product of the Last Reported Sale Price, Common Shares		98%						98%
Convertible Senior Notes, Percentage of Principal Required for Repurchase		100%						100%
Convertible Preferred Stock, Shares Issued upon Conversion | shares		61.6095						61.6095
Convertible Debt, Conversion Rate of Commmon Shares, Principal		$ 1,000						$ 1,000
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 16.23						$ 16.23
Convertible Debt Conversion Feature, Fair Value at Issuance							28,859,000
Convertible Debt Conversion Feature Gain (Loss)										$ 6,193,000
Convertible due 2022 - Bond Hedge, Fair Value at Issuance							$ 24,780,000
Derivative, Price Risk Option Strike Price | $ / shares							$ 21.4375
Issuance of warrants							$ 14,100,000
Debt Instrument, Net Proceeds							115,289,000
Debt Instrument, Net Carrying Amount		$ 0						$ 0				2,642,000
Debt Instrument, Fee Amount		$ 0						$ 0				$ (8,000)
Derivative, Amount of Hedged Item							$ (10,680,000)
Debt Instrument, Interest Rate, Effective Percentage		5.40%						5.40%
Debt Instrument, Increase, Accrued Interest		$ 20,000	$ 30,000					$ 50,000	$ 799,000
Debt Instrument, Interest Rate on Liability Component, Effective Percentage		10.90%						10.90%
Class of Warrant or Right, Outstanding | shares		7,393,141						7,393,141
Convertible Subordinated Debt | Convertible Senior Notes at 5.00% November 2024 [Domain]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Threshold Trading Days								10
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022
Debt Instrument [Line Items]
Debt Instrument, Repurchase Amount				$ 78,850,000
Convertible Subordinated Debt | Convertible Senior Subordinated Debentures at 5.00% February 2021 [Domain]
Debt Instrument [Line Items]
Unamortized Financing Costs								$ 625,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 | Subsequent Event
Debt Instrument [Line Items]
Interest rate (as a percent)											5.68%
Debt Instrument Repurchase Amount, Cash Paid											$ 4,500,000
Last Reported Sales Price Period, Common Stock	20 days
Percent of the Applicable Conversion Price											150%
Convertible Senior Notes, Percentage of Principal Required for Repurchase											100%
Convertible Debt, Conversion Rate of Commmon Shares, Principal											$ 1,000
Debt Instrument, Common Shares Exchanged | shares	2,700,000
Convertible Senior Notes, Holders Aggregate Principal Minimum requirement percentage, in the event of default											25%
Convertible Senior Notes, Additional Accrued interest in the Event of Failure to File Requirements under SEC Act of 1934											0.50%
Convertible Senior Notes, Additional Accrued interest in the Event of restrictive legends not being removed as of the 380th day after date of original issuance											0.50%
Debt Instrument, Percent limit on issuing common shares upon Conversion of the New 2026 Notes											19.99%
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 | First year of loan period | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Prepayment Premium, Percentage of aggregate principal amount	1%
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 | Year 2 and on | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Prepayment Premium, Percentage of aggregate principal amount	1%
Debt Instrument, Additional Prepayment Premium, Percentage of aggregate principal amount	3%
Secured Debt | Secured Term Loans due July 2026 [Domain] | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 104,500,000
Debt instrument, Springing Maturity Date	91 days
Debt Instrument, Debt Default, Amount											20,000,000
Secured Debt | Secured Term Loans due July 2026 [Domain] | Subsequent Event | Initial amount at closing [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											66,500,000
Secured Debt | Secured Term Loans due July 2026 [Domain] | Subsequent Event | Additional amount after closing (round 2) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											8,500,000
Secured Debt | Secured Term Loans due July 2026 [Domain] | Subsequent Event | Additional amount after closing (round 3) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											10,000,000
Secured Debt | Secured Term Loans due July 2026 [Domain] | Subsequent Event | Additional amount after closing (round 4) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											19,500,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain] | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 20,739,000
Interest rate (as a percent)											5.68%
Convertible Preferred Stock, Shares Issued upon Conversion | shares											333.3333
Convertible Debt, Conversion Rate of Commmon Shares, Principal											$ 1,000
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 3
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche I Notes [Domain] | Subsequent Event | Round 1 funding (Initial closing) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 15,553,000
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche II Notes [Domain] | Subsequent Event
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 20,736,000
Interest rate (as a percent)											5.68%
Convertible Preferred Stock, Shares Issued upon Conversion | shares											222.222
Convertible Debt, Conversion Rate of Commmon Shares, Principal											$ 1,000
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 4.50
Secured Debt | Convertible Senior Secured Notes at 5.68% July 2026 - Tranche II Notes [Domain] | Subsequent Event | Round 1 funding (Initial closing) [Domain]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 15,553,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Weighted average interest rate (as a percent)		4.50%						4.50%				4.50%
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding		$ 25,950,000						$ 25,950,000				$ 22,150,000
Borrowing capacity		60,000,000						60,000,000
Additional increase in borrowing capacity available		25,000,000						$ 25,000,000
Percentage of domestic accounts receivable								85%
Percentage of eligible domestic inventory and in-transit inventory								70%
Percentage of net orderly liquidation value of domestic inventory								85%
Maximum value of net orderly liquidation value domestic inventory and in-transit inventory		4,000,000						$ 4,000,000
Net orderly liquidation value of domestic eligible machinery and equipment								80%
Additional amount of machinery and equipment		0						$ 0
Percentage of eligible Canadian accounts receivable								85%
Percentage of eligible Canadian inventory								70%
Percentage of net orderly liquidation value of eligible Canadian inventory								85%
Minimum availability reserve		3,000,000						$ 3,000,000
Line of Credit Facility, Current Borrowing Capacity		26,809,000						26,809,000
Line of Credit Facility, Covenant Feature, Dominion Trigger		$ 7,500,000						$ 7,500,000
Minimum required undrawn balance (as a percent)		11.25%						11.25%
Line of Credit, Covenant Compliance, Consecutive Business Days for Undrawn_Balance								5 days
Interruption of material manufacturing facilities, period								10 days
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)		$ 8,803,000						$ 8,803,000				7,366,000
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)		4,412,000						4,412,000				5,986,000
Line Of Credit Facility Gross Borrowing Base		41,324,000						41,324,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | Euro Member Countries, Euro
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (France)		8,200,000						8,200,000				6,500,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) | United Kingdom, Pounds
Debt Instrument [Line Items]
Line of Credit Facility, Foreign Currency Fair Value of Amount Outstanding (UK)		3,500,000						3,500,000				4,500,000
Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement) | Subsequent Event
Debt Instrument [Line Items]
Borrowing capacity											35,000,000
Minimum availability reserve											$ 3,000,000
Debt Instrument, Springing Maturity Date, days prior to maturity of Convertible Notes due 2024	191 days
Debt Instrument, Springing Maturity, days prior to maturity of secured term loans due 2026	100 days
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity		30,000,000						$ 30,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Europe, Percent								85%
Minimum availability reserve		3,000,000						$ 3,000,000
Line of Credit Facility, Covenant Feature, Dominion Trigger		3,750,000						3,750,000
Line of Credit Facility, Remaining Borrowing Capacity		13,205,000						13,205,000
Remaining borrowing capacity		$ 30,000,000						$ 30,000,000
Minimum required undrawn balance (as a percent)		12.50%						12.50%
Consecutive business days for minimum undrawn balance								5 days
Interruption of material manufacturing facilities, period								10 days
Line of Credit Facility, Covenant Feature Dominion Trigger for Five Consecutive Days		$ 3,750,000						$ 3,750,000
Line of Credit Facility, Covenant Feature, Prior Limit		10,000,000						10,000,000
Line of Credit Facility, Covenant Feature, Increase Limit Based on receivables		9,000,000						9,000,000
Line Of Credit Facility Gross Borrowing Base		$ 19,955,000						$ 19,955,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (North America Credit Agreement)
Debt Instrument [Line Items]
Minimum required undrawn balance (as a percent)		12.50%						12.50%
Letter of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Fair Value of Amount Outstanding		$ 4,015,000						$ 4,015,000				2,585,000
Letters of Credit Outstanding, Amount		3,392,000						3,392,000				$ 3,450,000
Letter of Credit | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity		20,000,000						20,000,000
Letter of Credit | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity		5,000,000						5,000,000
Swing Line Loans | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity		2,000,000						2,000,000
Amount Available to Invacare Limited and Invacare Poirier SAS | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Borrowing capacity		$ 15,000,000						$ 15,000,000
Base Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | First year of loan period | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	6%
Base Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | Year 2 and on | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	7.75%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | First year of loan period | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	7%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Secured Debt | Secured Term Loans due July 2026 [Domain] | Year 2 and on | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	8.75%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement) | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	3.25%
Prime Rate | Revolving Credit Facility | Line of Credit | Secured Revolving Credit and Security Agreement (ABL Credit Agreement) | Subsequent Event
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage								0.25%
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage								0.25%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								1.25%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.50%
Minimum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.25%
Minimum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.50%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage								0.375%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Commitment fee percentage								0.375%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								1.75%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								3%
Maximum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								2.75%
Maximum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement)
Debt Instrument [Line Items]
Basis spread on variable rate								3%

Long-Term Debt Sale Leaseback T

Long-Term Debt Sale Leaseback Transactions (Details)	Apr. 23, 2015 USD ($)
Sale Leaseback Transactions [Abstract]
Sale Leaseback Transaction, Deferred Gain, Gross	$ 7,414,000

Other Long-Term Obligations (De

Other Long-Term Obligations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Apr. 23, 2015
Other Liabilities Disclosure [Abstract]
Deferred income taxes	$ 20,961,000		$ 20,961,000		$ 21,664,000
Product liability	11,644,000		11,644,000		11,342,000
Pension	3,109,000		3,109,000		7,814,000
Deferred compensation	5,384,000		5,384,000		6,174,000
Deferred gain on sale leaseback, Net	5,005,000		5,005,000		5,174,000
Supplemental executive retirement plan liability	4,833,000		4,833,000		5,106,000
Death benefit obligation plan	3,654,000		3,654,000		4,568,000
Uncertain tax obligation including interest	3,093,000		3,093,000		3,171,000
Other	466,000		466,000		1,783,000
Other Long-Term Obligations	58,149,000		58,149,000		$ 66,796,000
Sale Leaseback Transaction, Deferred Gain, Gross						$ 7,414,000
Sale and Leaseback Transaction, Gain (Loss), Net	$ 82,000	$ 79,000	$ 163,000	$ 157,000

Leases and Commitments (Details

Leases and Commitments (Details) - USD ($)		3 Months Ended			6 Months Ended
	Apr. 23, 2015	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2015	Jun. 30, 2022	Jun. 30, 2021
Lessee, Lease, Description [Line Items]
Sale Leaseback Transaction, Lease Term					20 years
Sale and Leaseback Transaction, Gain (Loss), Net		$ 82,000	$ 79,000		$ 163,000	$ 157,000
Sale Leaseback Transaction, Annual Payments					$ 2,275,000
Sale Leaseback Transaction, Net Proceeds, Investing Activities				$ 23,000,000
Sale Leaseback Transaction, Lease Terms					Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives, consistent with any other company leases.
Sale Leaseback Transaction, Deferred Gain, Gross	$ 7,414,000
Sale Leaseback Transaction, Immediate Loss Recognized	257,000
Capital Lease Obligations	$ 32,339,000
Minimum
Lessee, Lease, Description [Line Items]
General Lease Term					1 year
Maximum
Lessee, Lease, Description [Line Items]
General Lease Term					20 years

Leases and Commitments Lease Ex

Leases and Commitments Lease Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating Lease, Expense	$ 1,420	$ 1,819	$ 3,030	$ 3,781
Short-term Lease, Cost	631	1,010	1,345	2,061
Operating Lease, Cost	2,051	2,829	4,375	5,842
Finance Lease, Interest Expense	1,079	1,163	2,162	2,341
Finance Lease, Right-of-Use Asset, Amortization	1,063	1,266	2,155	2,542
Financing Lease, Cost	$ 2,142	$ 2,429	$ 4,317	$ 4,883

Leases and Commitments Future M

Leases and Commitments Future Minimum Operating and Financing Lease Commitments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Finance Lease, Liability, Payments, Due Next Twelve Months	$ 3,416
2022	2,325
Finance Lease, Liability, Payments, Due Year Two	6,772
2023	2,990
Finance Lease, Liability, Payments, Due Year Three	6,716
Finance Lease, Liability, Payments, Due Year Four	6,620
Finance Lease, Liability, Payments, Due Year Five	6,508
2026	1,104
Finance Lease, Liability, Payments, Due after Year Five	68,436
Thereafter	1,634
Finance Lease, Liability, Payments, Due	98,468
Total future minimum lease payments	12,105
Financing Leases, Future Minimum Payments, Interest Included in Payments	(34,673)
Operating Leases, Future Minimum Payments, Interest Included in Payments	(1,497)
Financing Leases, Future Minimum Payments, Present Value of Net Minimum Payments	63,795
Operating Leases, Future Minimum Payments, Present Value of Net Minimum Payments	10,608
Finance Lease, Liability, Current	(3,085)	$ (3,009)
Operating Lease, Liability, Current	(3,551)	(4,217)
Financing Lease Liability, non-current	60,710
Operating Leases Long-Term Obligations	7,057	$ 8,234
2024	2,254
2025	$ 1,798

Leases and Commitments Suppleme

Leases and Commitments Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	$ 2,060	$ 2,897	$ 4,299	$ 5,917
Financing Leases, Cash Paid in Measurement of Amounts for Lease Liabilities	1,839	2,102	3,668	4,211
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	449	590	1,165	4,429
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	740	181	915	6,156
Right-of-Use Asset Obtained in Exchange for Total Lease Liability	1,189	771	2,080	10,585
Total Cash Paid in Measurement of Amounts for Lease Liabilities	$ 3,899	$ 4,999	$ 7,967	$ 10,128

Leases and Commitments Weighted

Leases and Commitments Weighted-Average Remaining Lease Terms and Discount Rates (Details)	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Finance Lease, Weighted Average Remaining Lease Term	15 years 2 months 12 days	15 years 9 months 18 days
Operating Lease, Weighted Average Remaining Lease Term	4 years 10 months 24 days	5 years
Finance Lease, Weighted Average Discount Rate, Percent	6.42%	6.43%
Operating Lease, Weighted Average Discount Rate, Percent	7.08%	7.10%

Revenue (Details)

Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 189,017,000	$ 225,864,000	$ 390,005,000	$ 422,066,000
Net Revenue	100%	100%	100%	100%
Deferred Revenue	$ 2,404,000		$ 2,404,000		$ 4,156,000
Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 184,309,000	$ 221,194,000	$ 381,139,000	$ 412,918,000
Net Revenue	98%	98%	98%	98%
Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 4,708,000	$ 4,670,000	$ 8,866,000	$ 9,148,000
Net Revenue	2%	2%	2%	2%
Europe (EMEA)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 112,768,000	$ 121,296,000	$ 230,847,000	$ 234,071,000
Europe (EMEA) | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	109,479,000	118,165,000	224,744,000	228,009,000
Europe (EMEA) | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	3,289,000	3,131,000	6,103,000	6,062,000
North America (NA)
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	68,718,000	96,247,000	144,037,000	172,221,000
North America (NA) | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	68,525,000	95,985,000	143,708,000	171,687,000
North America (NA) | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	193,000	262,000	329,000	534,000
All Other
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	7,531,000	8,321,000	15,121,000	15,774,000
All Other | Product
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	6,305,000	7,044,000	12,687,000	13,222,000
All Other | Service
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Net Sales	$ 1,226,000	$ 1,277,000	$ 2,434,000	$ 2,552,000
General Terms and Conditions
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split			30%
Large National Customers
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split			23%
Government Tenders
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split			22%
Other Customers
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Contract Type Sales Split			25%

Equity Compensation (Narrative)

Equity Compensation (Narrative) (Details) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) votes $ / shares shares	Jun. 30, 2021 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.25		$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Description				The 2018 Plan uses a fungible share-counting method, under which each Common Share underlying an award of stock options or stock appreciation rights ("SAR") will count against the number of total shares available under the 2018 Plan as one share; and each Common Share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2018 Plan as two shares. Shares underlying awards made under the 2003 Plan or 2013 Plan that are forfeited or remain unpurchased or undistributed upon termination or expiration of the awards will become available under the 2018 Plan for use in future awards. Any Common Shares that are added back to the 2018 Plan as the result of forfeiture, termination or expiration of an award granted under the 2018 Plan or the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2018 Plan or 2013 Plan, as applicable. Each Common Share that is added back to the 2018 Plan due to a forfeiture, termination or expiration of an award granted under the 2003 Plan will be added back as one Common Share.
Allocated Share-based Compensation Expense | $		$ 26	$ 713	$ (319)	$ 1,381
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense | $				$ 2,278	5,810
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award requisite service period				3 years
Performance achievement level, lower range				0%
Performance achievement level, upper range				150%
Performance achievement level, target range				100%
Performance Shares | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense | $				$ (319)	$ 2,049
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares	[1]	2,362,474		2,362,474
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Share Awards Underlying from 2003 Plan | shares		805,637		805,637
Weighted Average | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for recognition of unrecognized compensation costs				3 years
Class B Common Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Number of Votes | votes				10
Common Stock, Shares, Issued | shares		3,667		3,667
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Holders Percentage of Total Outstanding				99.90%
[1] *    Shares available for grant under the 2018 Plan as of June 30, 2022 are reduced by awards and increased by forfeitures or expirations. At June 30, 2022, an aggregate of 805,637 Common Shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer.

Equity Compensation Share-based

Equity Compensation Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 26	$ 713	$ (319)	$ 1,381
Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense			2,278	5,810
Restricted Stock and Restricted Stock Units (RSUs) | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense			2,597	3,761
Performance Shares | Selling, General and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense			$ (319)	$ 2,049

Equity Compensation Unrecognize

Equity Compensation Unrecognized Compensation Expense (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 6,218
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	1,354
Restricted Stock and Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 4,864

Equity Compensation (Options Ac

Equity Compensation (Options Activity) (Details)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding at beginning of period (in shares) | shares	750,159
Canceled (in shares) | shares	(3,000)
Options outstanding at end of period (in shares) | shares	747,159
Weighted Average Exercise Price
Options outstanding at beginning of period - Weighted Average Exercise Price (in dollars per share)	$ 12.69
Canceled - Weighted Average Exercise Price (in dollars per share)	17.47
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	$ 12.67
Options exercisable at end of period (in shares) | shares	747,159
Stock Options
Weighted Average Exercise Price
Options available for grant at end of period (in shares) | shares	2,362,474	[1]
$12.15 – $20.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, lower limit (in dollars per share)	$ 12.15
$12.15 – $20.00 | Stock Options
Weighted Average Exercise Price
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)	12.67
Range of Exercise Price Max [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price range, upper limit (in dollars per share)	$ 14.49
[1] *    Shares available for grant under the 2018 Plan as of June 30, 2022 are reduced by awards and increased by forfeitures or expirations. At June 30, 2022, an aggregate of 805,637 Common Shares underlie awards which were forfeited or expired unexercised under the 2003 and 2013 Plans and thus are available for future issuance under the 2018 Plan upon transfer.

Equity Compensation (Stock Opti

Equity Compensation (Stock Options Outstanding by Exercise Price) (Details) - $ / shares	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 12.67	$ 12.69
$12.15 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per share)	12.15
$12.15 – $20.00 | Minimum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	12.15
$12.15 – $20.00 | Maximum
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, upper limit (in dollars per share)	$ 20
Stock Options | $12.15 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Number Outstanding at end of period (in shares)	747,159
Options Outstanding - Weighted Average Remaining Contractual Life	3 years 6 months
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 12.67
Options Exercisable - Number Exercisable At end of period (in shares)	747,159
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 12.67

Equity Compensation Restricted

Equity Compensation Restricted Stock Activity (Details) - Restricted Stock and Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance | shares	1,160,847
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares	1,017,055
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares	(131,256)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | shares	1,496,872
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 8.17
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	1.48
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares	6.94
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 3.64
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | shares	549,774
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 8.43

Equity Compensation Performance

Equity Compensation Performance Share Activity (Details) - Performance Shares - $ / shares	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	1,432,475	972,288
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 5.75	$ 7.76
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	460,187
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.48

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) by Component (Changes in Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	$ 11,694	$ 50,670	$ 16,988	$ 45,436
OCI before reclassifications	(20,983)	5,968	(26,132)	10,897
Amount reclassified from accumulated OCI	(595)	441	(740)	746
Other Comprehensive Income (Loss)	(21,578)	6,409	(26,872)	11,643
Ending Balance	(9,884)	57,079	(9,884)	57,079
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	12,193	53,131	18,961	50,329
OCI before reclassifications	(25,540)	7,250	(32,308)	10,052
Amount reclassified from accumulated OCI	0	0	0	0
Other Comprehensive Income (Loss)	(25,540)	7,250	(32,308)	10,052
Ending Balance	(13,347)	60,381	(13,347)	60,381
Accumulated Long-Term Notes Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	2,553	2,358	2,127	(517)
OCI before reclassifications	(1,005)	(212)	(579)	2,663
Amount reclassified from accumulated OCI	0	0	0	0
Other Comprehensive Income (Loss)	(1,005)	(212)	(579)	2,663
Ending Balance	1,548	2,146	1,548	2,146
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(3,877)	(3,325)	(4,101)	(3,674)
OCI before reclassifications	4,299	(701)	4,617	(231)
Amount reclassified from accumulated OCI	40	(43)	(54)	(164)
Other Comprehensive Income (Loss)	4,339	(744)	4,563	(395)
Ending Balance	462	(4,069)	462	(4,069)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	825	(1,494)	1	(702)
OCI before reclassifications	1,263	(369)	2,138	(1,587)
Amount reclassified from accumulated OCI	(635)	484	(686)	910
Other Comprehensive Income (Loss)	628	115	1,452	(677)
Ending Balance	$ 1,453	$ (1,379)	$ 1,453	$ (1,379)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income (Loss) by Component (Reclassified Out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of Products Sold	$ 141,035	$ 165,046	$ 294,294	$ 306,610
Amortization of prior service costs and unrecognized gains	58,623	63,765	119,187	122,586
Income tax provision	(920)	(1,120)	(2,240)	(2,990)
Net Sales	(189,017)	(225,864)	(390,005)	(422,066)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of prior service costs and unrecognized gains	(40)	(43)	54	164
Income tax provision	0	0	0	0
Net loss from Continuing Operations	40	(43)	(54)	(164)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income (Loss) from Continuing Operations before Income Taxes	(733)	545	(791)	1,019
Income tax provision	98	(61)	105	(109)
Net loss from Continuing Operations	(635)	484	(686)	910
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of Products Sold	703	386	734	(838)
Net Sales	$ (30)	$ (159)	$ (57)	$ (181)

Charges Related To Restructur_3

Charges Related To Restructuring Activities (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 2,936,000	$ 482,000		$ 482,000
Charges	4,153,000	3,790,000	$ 547,000	7,943,000	$ 2,099,000
Payments	(3,088,000)	(1,336,000)		(4,424,000)	(6,824,000)
Ending Balance	4,001,000	2,936,000		4,001,000
Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	2,936,000	482,000		482,000
Charges	1,830,000	3,252,000
Payments	(2,022,000)	(798,000)
Ending Balance	2,744,000	2,936,000		2,744,000
Other Restructuring
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0		0
Charges	2,323,000	538,000
Payments	(1,066,000)	(538,000)
Ending Balance	1,257,000	0		1,257,000
North America (NA)
Restructuring Reserve [Roll Forward]
Beginning Balance	1,184,000	482,000		482,000
Charges	1,540,000	1,662,000	31,000	3,202,000	853,000
Restructuring Reserve, Accrual Adjustment	1,540,000			3,202,000
Payments	(1,210,000)	(960,000)
Ending Balance	1,514,000	1,184,000		1,514,000
North America (NA) | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	1,184,000	482,000		482,000
Charges	542,000	1,124,000			853,000
Payments	(768,000)	(422,000)
Ending Balance	958,000	1,184,000		958,000
North America (NA) | Other Restructuring
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0		0
Charges	998,000	538,000
Payments	442,000	538,000
Ending Balance	556,000	0		556,000
Europe (EMEA)
Restructuring Reserve [Roll Forward]
Beginning Balance	1,752,000
Charges	2,613,000	2,119,000	516,000	4,732,000	1,246,000
Payments	(1,878,000)	(367,000)
Ending Balance	2,487,000	1,752,000		2,487,000
Europe (EMEA) | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	1,752,000
Charges	1,288,000	2,119,000			862,000
Payments	(1,254,000)	(367,000)
Ending Balance	1,786,000	1,752,000		1,786,000
Europe (EMEA) | Contract Termination
Restructuring Reserve [Roll Forward]
Charges					384,000
Europe (EMEA) | Other Restructuring
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Charges	1,325,000	0
Payments	624,000	0
Ending Balance	701,000	0		701,000
All Other
Restructuring Reserve [Roll Forward]
Charges	$ 0	9,000	$ 0	$ 9,000	$ 0
Payments		(9,000)
All Other | Severance
Restructuring Reserve [Roll Forward]
Charges		9,000
Payments		(9,000)
All Other | Other Restructuring
Restructuring Reserve [Roll Forward]
Payments		$ 0

Charges Related To Restructur_4

Charges Related To Restructuring Activities Narrative (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Restructuring Cost and Reserve [Line Items]
Charges	$ 4,153,000	$ 3,790,000	$ 547,000	$ 7,943,000	$ 2,099,000
Restructuring and Related Activities, Expected Payout Period	12 months			12 months
Payments	$ (3,088,000)	(1,336,000)		$ (4,424,000)	(6,824,000)
Severance
Restructuring Cost and Reserve [Line Items]
Charges	1,830,000	3,252,000
Payments	(2,022,000)	(798,000)
North America (NA)
Restructuring Cost and Reserve [Line Items]
Charges	1,540,000	1,662,000	31,000	3,202,000	853,000
Restructuring Reserve, Accrual Adjustment	1,540,000			3,202,000
Payments	(1,210,000)	(960,000)
North America (NA) | Severance
Restructuring Cost and Reserve [Line Items]
Charges	542,000	1,124,000			853,000
Payments	(768,000)	(422,000)
Europe (EMEA)
Restructuring Cost and Reserve [Line Items]
Charges	2,613,000	2,119,000	516,000	4,732,000	1,246,000
Payments	(1,878,000)	(367,000)
Europe (EMEA) | Severance
Restructuring Cost and Reserve [Line Items]
Charges	1,288,000	2,119,000			862,000
Payments	(1,254,000)	(367,000)
Europe (EMEA) | Contract Termination
Restructuring Cost and Reserve [Line Items]
Charges					384,000
All Other
Restructuring Cost and Reserve [Line Items]
Charges	$ 0	9,000	$ 0	$ 9,000	$ 0
Payments		(9,000)
All Other | Severance
Restructuring Cost and Reserve [Line Items]
Charges		9,000
Payments		$ (9,000)

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Valuation Allowance [Line Items]
Effective income tax rate, continuing operations	(4.40%)	(11.70%)	(5.10%)	(13.70%)
U.S. statutory income tax rate			21%
Effective income tax rate, continuing operations	(4.40%)	(11.70%)	(5.10%)	(13.70%)
U.S. statutory income tax rate			21%

Net Earnings (Loss) Per Commo_3

Net Earnings (Loss) Per Common Share Computation of Basic and Diluted Net Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net Loss per Share—Basic
Average common shares outstanding		35,634	34,969	35,340	34,732
Net Loss		$ (21,943)	$ (10,698)	$ (46,140)	$ (24,742)
Net earnings (loss) per common share		$ (0.62)	$ (0.31)	$ (1.31)	$ (0.71)
Loss per Share—Assuming Dilution
Average common shares outstanding		35,634	34,969	35,340	34,732
Stock options and awards		361	651	374	718
Average common shares assuming dilution		35,995	35,620	35,714	35,450
Net Loss		$ (21,943)	$ (10,698)	$ (46,140)	$ (24,742)
Net earnings (loss) per per common share—assuming dilution (in dollars per share)	[1]	$ (0.62)	$ (0.31)	$ (1.31)	$ (0.71)
[1]Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Net Earnings (Loss) Per Commo_4

Net Earnings (Loss) Per Common Share Textuals (Details) - Stock Options - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,680,850	1,058,264	1,268,582	1,056,714
Antidilutive share granted, average exercise price	$ 12.14	$ 24.45	$ 12.14	$ 24.45
Fair value stock price	$ 1.32	$ 8.33	$ 1.73	$ 8.81

Concentration Of Credit Risk (D

Concentration Of Credit Risk (Details)	Jun. 30, 2022 USD ($)
Risks and Uncertainties [Abstract]
Retained Recourse Obligation For Events Of Default Under Contracts	$ 1,019,000
Events of Default Under Contract by Third Party	$ 6,613,000

Derivatives Notional Amounts -

Derivatives Notional Amounts - Designated as Hedges (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	$ 148,779	$ 120,242
Gain (Loss)	(4,635)	(1,553)
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	52,704	23
Unrealized Gain (Loss)	1,693	1
USD / CAD | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	11,750	0
Unrealized Gain (Loss)	(49)	0
USD / EUR | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	23,147	0
Unrealized Gain (Loss)	1,452	0
USD / MXN | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	2,209	23
Unrealized Gain (Loss)	106	1
EUR / GBP | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	5,928	0
Gain (Loss)	115	0
EUR / GBP | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	9,353	0
Unrealized Gain (Loss)	181	0
EUR / SEK | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	6,797	0
Gain (Loss)	(153)	0
EUR / NOK | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	5	0
Gain (Loss)	0	0
EUR / NOK | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	3,932	0
Unrealized Gain (Loss)	19	0
AUD / NZD | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	7,517	7,366
Gain (Loss)	(36)	(17)
NOK / SEK | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	2,313	0
Unrealized Gain (Loss)	(16)	0
USD / THB | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Notional Amount	4,270	4,500
Gain (Loss)	$ (46)	$ 86

Derivatives Notional Amounts _2

Derivatives Notional Amounts - Not Designated as Hedges (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Derivative [Line Items]
Notional Amount		$ 148,779		$ 120,242
Gain (Loss)		(4,635)		(1,553)
Forward exchange contracts—net
Derivative [Line Items]
Gain (Loss)	$ 264		$ (723)
USD / AUD
Derivative [Line Items]
Notional Amount		1,299		3,792
Gain (Loss)		1		(57)
USD / CAD
Derivative [Line Items]
Notional Amount		19,084		14,556
Gain (Loss)		(10)		(24)
USD / DKK
Derivative [Line Items]
Notional Amount		12,352		10,850
Gain (Loss)		(714)		(257)
USD / GBP
Derivative [Line Items]
Notional Amount		3,717		4,028
Gain (Loss)		(63)		32
USD / NOK
Derivative [Line Items]
Notional Amount		5,352		2,352
Gain (Loss)		(579)		(81)
USD / SEK
Derivative [Line Items]
Notional Amount		2,152		2,344
Gain (Loss)		(196)		(131)
AUD / NZD
Derivative [Line Items]
Notional Amount		7,517		7,366
Gain (Loss)		(36)		(17)
USD / THB
Derivative [Line Items]
Notional Amount		4,270		4,500
Gain (Loss)		(46)		86
EUR / GBP
Derivative [Line Items]
Notional Amount		5,928		0
Gain (Loss)		115		0
EUR / NOK
Derivative [Line Items]
Notional Amount		5		0
Gain (Loss)		0		0
EUR / USD
Derivative [Line Items]
Notional Amount		80,306		70,454
Gain (Loss)		$ (2,954)		$ (1,104)

Derivatives Balance Sheet Locat

Derivatives Balance Sheet Location (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Other Current Assets
Derivatives, Fair Value [Line Items]
Derivative assets	$ 2,058	$ 386
Other Current Assets | Foreign currency forward contracts | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative assets	1,782	1
Other Current Assets | Foreign currency forward contracts | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative assets	276	385
Accrued Expenses
Derivatives, Fair Value [Line Items]
Derivative liabilities	5,000	1,938
Accrued Expenses | Foreign currency forward contracts | Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative liabilities	89	0
Accrued Expenses | Foreign currency forward contracts | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 4,911	$ 1,938

Derivatives Gain (Loss) in Stat

Derivatives Gain (Loss) in Statement of Finacial Position (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)	$ (733,000)	$ 545,000	$ (791,000)	$ 1,019,000
Foreign currency forward contracts | Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	1,263,000	(369,000)	2,138,000	(1,587,000)
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	635,000	(484,000)	686,000	(910,000)
Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	$ 115,000	(88,000)	115,000	(88,000)
Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)			$ (4,635,000)		$ (1,553,000)
Not Designated as Hedging Instrument [Member] | Foreign currency forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss)		$ 264,000		$ (723,000)

Derivatives Narrative (Details)

Derivatives Narrative (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2017	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Foreign currency forward contracts
Derivative [Line Items]
Notional amount of derivatives, matured during period	$ 27,998,000	$ 31,448,000		$ 38,664,000	$ 58,115,000
Selling, General and Administrative Expenses | Foreign currency forward contracts
Derivative [Line Items]
Gain (Loss)	(5,237,000)			$ (4,635,000)
Minimum
Derivative [Line Items]
Derivative, percentage of forcasted transactions with currency rate exposure				50%
Maximum
Derivative [Line Items]
Derivative, percentage of forcasted transactions with currency rate exposure				90%
Cash Flow Hedging [Member]
Derivative [Line Items]
Gain (Loss)	733,000	(545,000)		$ 791,000	(1,019,000)
Cash Flow Hedging [Member] | Sales [Member]
Derivative [Line Items]
Gain (Loss)	30,000	159,000		57,000	181,000
Cash Flow Hedging [Member] | Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss)	703,000	$ 386,000		734,000	$ 838,000
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Derivative [Line Items]
Proceeds from Issuance of Warrants			$ 14,100,000
Debt Instrument, Face Amount	$ 0		$ 120,000,000	$ 0		$ 2,650,000
Interest rate (as a percent)	4.50%			4.50%

Derivatives Fair Value of Conve

Derivatives Fair Value of Convertible Debt Hedges (Details)	12 Months Ended
	Dec. 31, 2019 USD ($)
Convertible Subordinated Debt | Convertible Senior Notes at 4.50% February 2022 [Domain]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Convertible Debt Conversion Feature Gain (Loss)	$ (6,193,000)

Fair Values (Assets and Liabili

Fair Values (Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Forward exchange contracts—net - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	(2,942)	(1,552)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0

Fair Values (Details of Book Va

Fair Values (Details of Book Value and Fair Value of Financial Instruments) (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents		$ 83,745	$ 78,252	$ 105,298
Cash and cash equivalents	$ 43,909	83,745
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	43,909
Cash and cash equivalents		83,745
Debt Instrument, Fair Value Disclosure	(313,650)	(308,129)
Carrying Value | Convertible Senior Notes at 4.50% February 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	0	(2,642)
Carrying Value | Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(72,274)	(72,140)
Carrying Value | Series II Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(80,248)	(78,251)
Carrying Value | Other Notes and Capital Lease Obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(41,383)	(36,060)
Carrying Value | Convertible Senior Notes at 4.25% March 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(119,745)	(119,036)
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	43,909	83,745
Debt Instrument, Fair Value Disclosure	(232,323)	(259,472)
Fair Value | Convertible Senior Notes at 4.50% February 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	0	(2,632)
Fair Value | Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(63,976)	(64,897)
Fair Value | Series II Convertible Senior Notes at 5.00% November 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(68,845)	(74,165)
Fair Value | Other Notes and Capital Lease Obligations
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(41,383)	(36,060)
Fair Value | Convertible Senior Notes at 4.25% March 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Fair Value Disclosure	(58,119)	(81,718)
Foreign currency forward contracts | Other Current Assets | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets	2,058	386
Foreign currency forward contracts | Other Current Assets | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets	2,058	386
Foreign currency forward contracts | Accrued Expenses | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	(5,000)	(1,938)
Foreign currency forward contracts | Accrued Expenses | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	(5,000)	(1,938)
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1 [Member] | Foreign currency forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets (liabilities), at fair value, net	0	0
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2 | Foreign currency forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets (liabilities), at fair value, net	(2,942)	(1,552)
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 [Member] | Foreign currency forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0

Business Segments (Information

Business Segments (Information by Segment) (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net Sales	$ 189,017,000		$ 225,864,000	$ 390,005,000	$ 422,066,000
Restructuring Reserve	4,001,000	$ 2,936,000		4,001,000		$ 482,000
Charges	(4,153,000)	(3,790,000)	(547,000)	(7,943,000)	(2,099,000)
Operating Loss	(14,794,000)		(3,494,000)	(31,419,000)	(9,229,000)
Interest Revenue (Expense), Net	(6,229,000)		(6,084,000)	(12,481,000)	(11,814,000)
Earnings (loss) before income taxes	(21,023,000)		(9,578,000)	(43,900,000)	(21,752,000)
Loss on debt extinguishment including debt finance charges and fees	0		0	0	(709,000)
Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	112,768,000		121,296,000	230,847,000	234,071,000
Restructuring Reserve	2,487,000	1,752,000		2,487,000
Charges	(2,613,000)	(2,119,000)	(516,000)	(4,732,000)	(1,246,000)
Operating Loss	3,489,000		4,992,000	6,714,000	8,824,000
North America (NA)
Segment Reporting Information [Line Items]
Net Sales	68,718,000		96,247,000	144,037,000	172,221,000
Restructuring Reserve	1,514,000	1,184,000		1,514,000		482,000
Restructuring Reserve, Accrual Adjustment	1,540,000			3,202,000
Charges	(1,540,000)	(1,662,000)	(31,000)	(3,202,000)	(853,000)
Operating Loss	(6,264,000)		1,590,000	(14,600,000)	(785,000)
All Other
Segment Reporting Information [Line Items]
Net Sales	7,531,000		8,321,000	15,121,000	15,774,000
Charges	0	(9,000)	0	(9,000)	0
Operating Loss	(7,866,000)		(9,529,000)	(15,590,000)	(15,169,000)
Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	112,768,000		121,296,000	230,847,000	234,071,000
Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	68,718,000		96,247,000	144,037,000	172,221,000
Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	7,531,000		8,321,000	15,121,000	15,774,000
Intersegment revenues
Segment Reporting Information [Line Items]
Net Sales	11,569,000		22,893,000	27,100,000	42,396,000
Intersegment revenues | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	4,129,000		6,229,000	8,564,000	11,537,000
Intersegment revenues | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	7,440,000		16,664,000	18,536,000	30,859,000
Severance
Segment Reporting Information [Line Items]
Restructuring Reserve	2,744,000	2,936,000		2,744,000		482,000
Charges	(1,830,000)	(3,252,000)
Severance | Europe (EMEA)
Segment Reporting Information [Line Items]
Restructuring Reserve	1,786,000	1,752,000		1,786,000
Charges	(1,288,000)	(2,119,000)			(862,000)
Severance | North America (NA)
Segment Reporting Information [Line Items]
Restructuring Reserve	958,000	1,184,000		958,000		$ 482,000
Charges	(542,000)	(1,124,000)			(853,000)
Severance | All Other
Segment Reporting Information [Line Items]
Charges		$ (9,000)
Contract Termination | Europe (EMEA)
Segment Reporting Information [Line Items]
Charges					(384,000)
Lifestyle Products [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	54,997,000		61,647,000	116,061,000	119,945,000
Lifestyle Products [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	33,836,000		40,100,000	68,137,000	76,285,000
Lifestyle Products [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	2,988,000		2,982,000	5,678,000	5,506,000
Mobility and Seating [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	47,830,000		51,903,000	95,232,000	96,125,000
Mobility and Seating [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	26,001,000		31,096,000	51,423,000	53,829,000
Mobility and Seating [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	2,857,000		2,850,000	5,683,000	6,068,000
Respiratory Therapy [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	4,922,000		3,350,000	9,585,000	9,388,000
Respiratory Therapy [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	8,688,000		24,789,000	24,148,000	41,573,000
Respiratory Therapy [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	352,000		1,050,000	1,131,000	1,332,000
Other [Domain] | Operating Segments [Member] | Europe (EMEA)
Segment Reporting Information [Line Items]
Net Sales	5,019,000		4,396,000	9,969,000	8,613,000
Other [Domain] | Operating Segments [Member] | North America (NA)
Segment Reporting Information [Line Items]
Net Sales	193,000		262,000	329,000	534,000
Other [Domain] | Operating Segments [Member] | All Other
Segment Reporting Information [Line Items]
Net Sales	$ 1,334,000		$ 1,439,000	$ 2,629,000	$ 2,868,000

Contingencies Contingencies (De

Contingencies Contingencies (Details)	Jun. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Liquidated Damages amount per violation per day	$ 15,000
Liquidated Damages - Yearly Limit	$ 7,000,000